JP2002519327A - Indium photosensitizer for PDT - Google Patents

Abstract

  (57) [Summary] The invention disclosed herein relates to a pyrrole nucleus for phototherapy complexed with a non-radioactive indium atom. Complexation of indium with the pyrrole nuclei results in metal pyrrole compounds, whose efficacy can localize these compounds to target sites in phototherapy. In this way, the therapeutic method is improved by acting functionally in both the detection of the diseased site and the phototherapy, or by imparting the functionality of binding to a receptor-specific site in the target area.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

[Technical field and background art]

Porphyrins and related pyrrole-based macrocycles, especially tetrapyrrole macrocycles, and many other light-absorbing compounds are commonly used in the context of photosensitizing drugs, especially in the field of photodynamic therapy (PDT) ^1. Has received a lot of attention. This treatment necessarily involves localizing the photosensitizer at or near the site of the disease.
The sensitizer, when emitted in the presence of oxygen, produces cytotoxic species of oxygen, such as atomic oxygen or oxygen radicals, which destroy diseased cells. Because the sensitizers are harmless at therapeutic doses and are only active when emitted by light of a particular wavelength, PDT is useful in other common ways (e.g., conventional chemotherapy). It provides a certain level of possible control or selectivity in the treatment of diseases that cannot be found. Photodynamic therapy is used to treat diseases such as cancer, cardiovascular restenosis, plaque, psoriasis,
It is widely applied to modern medicines targeting viral infections, benign prostate growth and diabetic retinopathy. In addition, photodynamic therapy can also be useful for blood sterilization, especially in the area of current AIDS and transfusions.
There is a high degree of concern in connection with HIV transmission.

[0002] Much work on PDT has focused on complex mixtures of less well-defined porphyrin dimers, trimers and oligomers ² . It is commercially available under the Photofrin II (Photofrin II ^R), entitled. This complex mixture has recently been approved by the Food & Drug Administration Advisory Panel for use in treating obstructive bronchial epithelial tumors. This mixture has proven to have a powerful advantage for PDT, but because of its composition,
It has several related disadvantages. For example, each of its components has varying cell localization properties depending on the inherent differences in structure and optical properties. This makes interpretation of the pharmacokinetic data difficult. Further, the composition of the oligomer is
It is often difficult to reproduce and varies depending on the conditions under which the solution ³ was stored. Thus, the true “active ingredient” can vary considerably. This mixture has a suboptimal light absorption profile (630 nm, ε ~ 3,000 cm ⁻¹ M ⁻¹ ). Many studies on the transmission of light through the tissue reveals that lower wavelengths of light is transmitted to a deeper tissue ^4. Although not all applications of PDT require deep penetration of light, many applications of PDT require the maximum possible light transmission depth (eg, treatment of brain tumors). This mixture has a significant adverse effect on normal skin response to light. This is often 12
Lasts up to ⁵ weeks. During this period, patients need to avoid high intensity light,
Otherwise severe burns and edema will result.

[0003] has been characterized some of the well, the second generation of the sensitizer ^{(SnET2 6, ZnPc 7, BPDMA} 8,
THPC ⁹ ) is generally in Phase I / II clinical research, and the continual development of new sensitizers with improved therapeutic efficacy is crucial to the future development of this therapy. is there. Developing new photosensitizers that have all of these basic requirements needed to be effective PDT drugs is not an easy task. Although the optimal photophysical properties of second generation drugs are well defined, the factors that help in localizing the photosensitizer to tissue are not well defined. Some researchers have attempted to elucidate the structure-activity relationship in a ring system that chemically modifies the photosensitizing compound without significantly affecting the physical properties of the compound. Woodburn and his colleagues, who work on similarity-based hematoporphyrins, show that anionic compounds tend to be localized in lysosomes, while cationic photosensitizers have been added to mitochondria. It has a tendency to be localized. Pandey and coworkers suggest that the lipophilicity of the compound is important, and that in a series of chlorophyll-derived substances, the PDT action varies with the length of the ether carbon chain of the compound. It revealed that. Unfortunately, many of the correlations seen in one group of photosensitizing compounds are not transmitted to the different groups of photosensitizing compounds. Thus, structure-activity relationships are beneficial for certain sets of compounds, where the geometry and spatial arrangement vary only slightly, but are inherently unique spatial and geometric parameters. The different sets of compounds with have to have their own structure-activity correlations considered. This is a very time consuming method and, ultimately, there is no guarantee that the modified compound will provide high localization or improved PDT efficiency.

[0004] The present invention is based on the discovery of a single, simple chemical modification of a compound having a pyrrole core, which modification coordinates a non-radioactive indium salt in the central cavity of the pyrrole core. , Forming an indium-pyrrole complex, which significantly enhances the biological efficiency of the compound as a photosensitizer for PDT. The two isotopes of indium, In ¹¹³ and In ¹¹⁵ , occur naturally, and the former (natural abundance: 4.23%) has no radioactivity, while the latter (natural abundance: 95.77%) ,
It has a half-life of 6 × 10 ¹⁴ years and as a result is also considered non-radioactive. Other indium nuclides have half-lives ranging from 50.0 years (for In ^{114 m} ) to 0.2 seconds (for In ^{109 m} ₂ ).

[0005] Tetrapyrroles containing In ¹¹¹ (half-life 2.81 days) and other metals are known in the art, for example, JP 1991-261786, US Patent 5,268,371 to Mauclaire et al. And Maier et al. No. 5,674,467, which also discloses their use for diagnostic imaging. The metal-tetrapyrrole compounds are all water-soluble and contain functional groups that can bind biologically active molecules, such as antibodies, to the tetrapyrrole nucleus. Usually, these compounds are prepared by reacting a porphyrin derivative with a solution of the salt of the metal to be complexed at a temperature and for a time sufficient to obtain the metal-tetrapyrrole compound. For example, when a metal salt containing In ¹¹¹ is heated at 110 ° C. for 3 hours in a porphyrin solution to which a mixture of acetic acid and sodium acetate is added, In ¹¹¹ -porphyrin is formed. The preparation of such metalloporphyrins is known and the compounds are discussed as radioimaging agents, but surprisingly, to the best of our knowledge, the effectiveness of indium porphyrins as therapeutic photosensitizers There are no reports on In light of important known technologies, including indium tetrapyrrole,
It is indeed surprising that complexes of radioactive indium with tetrapyrrole show a marked improvement in its cytotoxicity in vivo compared to other metallotetrapyrrole complexes. U.S. Pat.No. 4,849,207 to Sakata discloses compounds having the following structure:

[0006]

Embedded image

Here, R1, R2, R4 and R6 are methyl groups, R8, R10, R11 and R12 are H, and R7 and R9 are CH ₂ CH ₂ COR13 (where R13 is an amino acid R3 and R5 are ethyl groups, and In is not radioactive, ie, In ¹¹³ or In ¹¹⁵ . JP 5-97857 discloses compounds having the following structure:

[0008]

Embedded image

Here, R 1 is CH (OR) Me, R is an alkyl group, R 2 is a residue obtained by removing H from an amino acid, and M is 2H, Ga, Zn, Pd, In or Sn. The following references are cited above. 1. For an overview of photodynamic treatment, see Photodynamic treatment of neoplastic diseases (Photodynamic
Therapy of Neoplastic Disease), Vol. I & II, Keissel, D. ed., CRC Press
Published, 1990; 2. "Photodynamic Therapy of Neoplastic Disease
) ", Vol. I & II, Keissel, D. ed., CRC Press, 1990, p1-12; 3. Byrne, CJ, Ward, AD, Marshallsay, CJ, Photochem. Photobiol., 19
87, 46: 575; 4.a) Svaasand, LO, Ellingsen, R., Photochem. Photobiol., 1985, 41:73; b) Bolin, FP, Preuss, LE, Cain, BW, `` Localization of porphyrins Porphyrin Localization and Treatment of Tumours '', Doiron, DR
, Gomer, CJ, Alan Liss, NY, 211, 1984; 5. Razum, N., Balchum, OJ, Profio, AE, Carstens, C., Photochem. Phot.
obiol., 1987, 46: 925; 6. Kessel, D., Morgan, AR, Garbo, GM, Photochem. Photobiol., 1991, 5
4 (2): 193; 7.Ginevra, F., Biffanti, S., Pagnan, A., Biolo, R., Reddi, E., Jori, G.
, Cancer Letters, 1990, 49:59; 8. Aveline, B., Hasan, T., Redmond, RW, Photochem. Photobiol., 1994, 5
9 (3): 328; 9. Bonnett, R., White, RD, Winfield, U., Berenbaum, MC, Biochem. J.,
1989, 261: 277.

[0010]

DISCLOSURE OF THE INVENTION

One object of the present invention is to provide a pyrrole compound that absorbs long wavelength light for use in photodynamic therapy and diagnosis of disease states. Another object of the present invention is to provide (A) P (where P is a pyrrole derivative) and (B) In ¹¹³ X ₃ and / or In ¹¹⁵ X ₃ (where X is an organic or (Inorganic charge-balancing ions), for example the reaction product (C) P In ¹¹³ _n X _n and / or P In ¹¹⁵ _n X _n . Here, indium is coordinated with the pyrrole derivative, and n = 1, 2, and 3. It is a further object of the present invention to provide a reaction product of the nucleophile Y with (C) PIn ¹¹³ _{n Xn} and / or PIn ¹¹⁵ _{n Xn} , for example the reaction product (D) PIn ¹¹³ _n Y _n X _z and /
Or PIn ¹¹⁵ _n Y _n X _z is obtained, where Y is an organic or inorganic charge-balanced ion, n = 1,2,3 and z = 0,1,2,3. It is yet another object of the present invention to provide compounds PIn ¹¹³ X and / or PIn ¹¹⁵ X, which compounds include, for example, atherosclerosis, recurrent stenosis, cancer, cancer precursors, non-cancer Hyperproliferative diseases, psoriasis, macular degeneration, glaucoma and viral diseases,
It can be used to treat diseases such as benign prostatic hyperplasia, rheumatoid arthritis, and to help diagnose these disease states.

[0011]

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention provides derivatives of the photoactivatable compounds, some of which are exemplified in the following examples, Table 1 and FIGS. 1-5, through the introduction of non-radioactive indium into the macrocycle. . The resulting products can be used for the treatment and diagnosis of disease states. Also, the ligand on the indium complex can therefore be modified in vitro or in vivo, and further chemically or biochemically, to form a different pyrrole-based indium complex, which complex at the site in the disease state It can bind to important plasma components or cell transport proteins that enhance sensitizer uptake. Utilizing ancillary functionality near the pyrrole structure to attach biomolecules or other disease-specific molecules, such as antibodies, growth hormones and growth factors, or affect drug uptake in neoplastic disease tissues And other known factors such as solubility in water, lipophilicity or hydrophobicity. The following examples are intended to merely disclose and illustrate the present invention and are not intended to limit the invention in any way. In all of the procedures described in these examples, the indium used was natural indium, ie, about 4.23% In ¹¹³ and 95.77% In ^115.
Was a mixture with The following abbreviations are used in these examples: mL stands for milliliter, g is gram, mg is milligram, and μg is microgram.

[0012]

Embedded image

[0013] Methyl pyropheophorbide (0.5 g) is dissolved in acetic acid (100 mL), indium chloride (0.5 g) and anhydrous sodium acetate (0.5 g) are added, and the resulting solution is refluxed for 3 hours. did. The solution was evaporated to dryness on a rotary evaporator and the resulting solid residue was dissolved in dichloromethane / water (100 mL / 100 mL). The organic layer was washed several times with 0.5N HCl / water (200 mL), collected, and dried over anhydrous sodium sulfate (20 g). The organic layer was filtered and evaporated to dryness. The obtained residue was recrystallized from methanol / dichloromethane. The yield was 0.45 g.

[0014]

Embedded image

[0015] 4-t-butyl-1,2-dicyanobenzene (2 g) and indium chloride (2.0 g) were thoroughly mixed in a round bottom flask with stirring. The mixture was heated at 160 ° C. for 2 hours and the reaction vessel was cooled to room temperature. The crude phthalocyanine is extracted from the resulting green solid using hot dichloroethane, and the green solution is
Evaporated on a rotary evaporator. The resulting solid was dissolved in 7% acetone / dichloromethane and chromatographed on silica using 7% acetone / dichloromethane as eluent. The main green fraction was collected and recrystallized from methanol / dichloromethane.

[0016]

Embedded image

The ring B isomer, a benzoporphyrin derivative dimethyl ester (100 mg),
Dissolved in acetic acid (50 mL), indium chloride (0.2 g) and anhydrous sodium acetate (0.2 g) were added and the resulting solution was refluxed for 3 hours. This solution was evaporated to dryness on a rotary evaporator, and the obtained solid residue was dissolved in dichloromethane / water (100 mL / 100 mL). The resulting organic layer was washed several times with 0.5N HCl / water (200 mL), collected, and dried over anhydrous sodium sulfate (20 g). The organic layer was filtered and evaporated to dryness. The resulting residue was chromatographed on silica using 5% MeOH / dichloromethane as eluent and the main green fraction was collected. The solvent was removed on a rotary evaporator and the resulting solid was recrystallized from hexane / dichloromethane. Yield 5
It was 0 mg.

[0018]

Embedded image

[0019] Tetrakis (3-hydroxyphenyl) chlorin (100 mg) was dissolved in acetic acid and the resulting solution was purged with argon. Indium chloride (0.2 g) and anhydrous sodium acetate (0.2 g) were added and the resulting solution was refluxed for 3 hours under an argon atmosphere. The solution was evaporated to dryness on a rotary evaporator, and the resulting solid residue was dissolved in dichloromethane / water (100 mL / 100 mL). The obtained organic layer was washed several times with 0.5N HCl / water (20
0 mL), collected and dried over anhydrous sodium sulfate (20 g). The organic layer obtained was filtered and evaporated to dryness. The resulting residue was chromatographed on silica using 5% MeOH / dichloromethane as eluent and the main green fraction was collected. The solvent was removed on a rotary evaporator and the resulting solid was crystallized from hexane / dichloromethane. The yield was 60 mg.

[0020]

Embedded image

Octaethylbenzochlorin (100 mg) was dissolved in acetic acid, and indium chloride (0.2 g) was dissolved.
And anhydrous sodium acetate (0.2 g) were added. The resulting solution was refluxed for 3 hours under an argon atmosphere. The solution was evaporated to dryness on a rotary evaporator, and the resulting solid residue was dissolved in dichloromethane (10 mL). The resulting solution was chromatographed on silica using 5% MeOH / dichloromethane as eluent and the main green fraction was collected. The solvent was removed on a rotary evaporator and the resulting solid was crystallized from hexane / dichloromethane. The yield was 110 mg.

[0022]

Embedded image

OEBCSO_TwoNH (CH_Two)_ThreeOH (100 mg) was dissolved in dimethylformamide (DMF; 25 mL), and InCl _Three (100 mg) was added. The solution was refluxed for 6 hours, and DMF was removed on a rotary evaporator.
Removed. The obtained residue was dissolved in dichloromethane (10 mL), and the obtained solution was
Chromatography on silica using 5% MeOH / dichloromethane as eluent
-Processed. Collect and discard a small amount of the early spilling green band to make it more polar
The main green fraction was collected. The solvent is removed by a rotary evaporator,
The resulting solid was crystallized from hexane / dichloromethane. Yield is 52mg
Was.

[0024]

Embedded image

OEBCSO ₂ N (CH ₂ CH ₂ OCH ₂ CH ₂ OCH ₂ CH ₂ OCH ₂ CH ₂ OCH ₃ ) ₂ (400 mg) was dissolved in acetic acid (150 mL), and indium chloride (0.4 g) and anhydrous sodium acetate (0.4 g) were dissolved. 0.3 g) was added. This solution was refluxed for 3 hours under an argon atmosphere. The solution was evaporated to dryness on a rotary evaporator, and the resulting solid residue was dissolved in dichloromethane (10 mL).
The resulting solution was chromatographed on silica using 5% acetone / dichloromethane as eluent and the main green fraction was collected. The solvent was removed on a rotary evaporator and the resulting solid was crystallized from hexane / dichloromethane. The yield was 420 mg.

[0026]

Embedded image

OEBCSO ₂ NHC (CH ₂ OH) ₃ (100 mg) was dissolved in bromobenzene (50 mL), and indium chloride (0.2 g) and anhydrous sodium acetate (0.2 g) were added. The solution was refluxed for 5 hours under an argon atmosphere. The solution was evaporated to dryness on a rotary evaporator, and the resulting solid residue was dissolved in dichloromethane (10 mL). The resulting solution was chromatographed on silica using 5% acetone / dichloromethane as eluent and the main green fraction was collected. The solvent was removed on a rotary evaporator and the resulting solid was crystallized from hexane / dichloromethane. The yield was 105 mg.

[0028]

Embedded image

OEBCSO ₂ NH (CH ₂ ) ₄ CH (NH ₂ ) CO ₂ H (100 mg) was dissolved in acetic acid, and indium chloride (0.2
g) and anhydrous sodium acetate (0.2 g) were added. This solution is placed under an argon atmosphere
Refluxed for 3 hours. The solution was evaporated to dryness on a rotary evaporator, and the resulting solid residue was dissolved in dichloromethane (10 mL). The resulting solution was chromatographed on silica using 5% MeOH / dichloromethane as eluent and the main green fraction was collected. The solvent was removed on a rotary evaporator and the resulting solid was crystallized from hexane / dichloromethane. 110mg yield
Met.

[0030]

Embedded image

[0031] 2-Desvinyl 2-acetylpyropheophorbide (100 mg) was dissolved in acetic acid, and indium chloride (0.2 g) and anhydrous sodium acetate (0.2 g) were added. This solution was refluxed for 3 hours under an argon atmosphere. The solution was evaporated to dryness on a rotary evaporator, and the resulting solid residue was dissolved in dichloromethane (10 mL). The resulting solution was chromatographed on silica using 5% acetone / dichloromethane as eluent and the main green fraction was collected. The solvent was removed on a rotary evaporator and the resulting solid was crystallized from hexane / dichloromethane. The yield was 100 mg.

[0032]

Embedded image

[0033] 2-Desvinyl 2-formylpyropheophorbide (100 mg) was dissolved in acetic acid (20 mL) and indium chloride (100 mg) was added. Diisopropylethylamine (0.3 mL) was added and the resulting solution was refluxed until TLC (5% acetone / dichloromethane) no longer showed any starting material left. The acetic acid was removed on a rotary evaporator and the resulting residue was dissolved in dichloromethane and 10% NH ₄ Cl (2 × 50 mL)
And washed. The organic phase was separated, dried over sodium sulfate, filtered and evaporated to dryness on a rotary evaporator. This residue was dissolved in dichloromethane and purified by chromatography on silica using 5% acetone / dichloromethane as eluent and then 20% acetone / dichloromethane as eluent. The less polar green fraction was collected and recrystallized from dichloromethane / hexane. A second more polar green fraction was collected and discarded. The yield was (27) = 62 mg.

[0034]

Embedded image

Chlorin e6 trimethyl ester (150 mg) was dissolved in acetic acid (20 mL) and indium chloride (150 mg) was added. Diisopropylethylamine (0.3 mL) was added and TLC (5%
The resulting solution was refluxed until it was no longer confirmed by acetone / dichloromethane) that no starting material remained. The acetic acid was removed on a rotary evaporator and the resulting residue was dissolved in dichloromethane and washed with 10% NH ₄ Cl (2 × 50 mL). The organic phase was separated, dried over sodium sulfate, filtered and evaporated to dryness on a rotary evaporator. Dissolve the residue in dichloromethane and use 5% acetone as eluent
Purified by chromatography on silica using 20% acetone / dichloromethane followed by 20% acetone / dichloromethane as eluent. The main green fraction was collected and purified again by chromatography on silica using 5% acetone / dichloromethane as eluent. The main green fraction was collected and recrystallized from dichloromethane / hexane. The yield was 67 mg. Various compounds essentially containing a non-radioactive indium atom, complexed with the internal nitrogen of the pyrrole core, were evaluated for biological performance as photosensitizers. Some results of this evaluation are summarized below.

[0036]

Embedded image

The identities of the first group of these compounds tested (all of which had the following structure with any “sensitizer No.” given for reference purposes) and the process of preparation Here is an example (in some cases) where is described:

[0038]

[Table 1]

The identity of the second group of these compounds tested (all of which had the following structure, with any “sensitizer No.” given for reference purposes) and the process of preparation Here is an example (in some cases) where is described:

[0040]

Embedded image

[0041]

Embedded image

For biological evaluation, Chinese hamster lung fibroblasts (V-79) obtained from the American Tissue Culture Collection were incubated at 37 ° C. in D-MEM supplemented with 10% calf serum. Grow at 5% CO ₂ and 95% humidity. The cells were used to evaluate the sensitizer for dark and light toxicity, and uptake by cells. The medium was replaced with medium supplemented with 5% calf serum during the incubation of the sensitizer. In the first step, the intracellular and extracellular concentrations of the photosensitizer required to cause lethal damage to 50% of the cells in the culture under light irradiation ( DC (
The combination of 50)) was determined by plating the cells at a density of 100 cells / cm ² , incubating for 1-3 hours, and allowing the cells to attach. Added at non-toxic concentrations of DMSO / 5% dextrose, or in some cases egg yolk phosphatidase (
Cells were added to 16-cells with various concentrations of sensitizer ([C] = 0.01-1.0 μM) added in EYP).
Incubated for 24 hours. The cells were then irradiated with laser light at the band I absorption of the photosensitizer using a variable frequency Lexel argon pumped dye laser. The total output density was adjusted to 12.5 mW / cm ^2, and light irradiation was performed at a total light irradiation amount of 1.25 J / cm ² . After this treatment, cells were washed with HBSS and resupplied with DMEM containing phenol red, supplemented with 10% FBS,
Incubated for days to allow colony formation. Cells were fixed with methanol, stained with Giemsa, and colonies counted. The plating efficiency was determined using control colonies and the average survival was plotted against the sensitizer concentration to evaluate the DC50 as described above (Table 5).

Several photosensitizers were screened by standard cell uptake protocols. A stock solution of 10 μM photosensitizer in EYP was prepared by diluting the stock solution of photosensitizer (1 mM) with a 5% dextrose solution. Monolayer V-79 cells in exponential growth phase in 12-well tissue culture plates were harvested at 0, 12, 36, and 48 hours for 0.
Incubated with 2 mL of the 10 μM photosensitizer solution. Following this incubation, the cells are washed three times with PBS (1 mL) and then with HBSS (1 mL) and 100 μL
Using trypsin. Individual wells containing cells were lysed by three freeze-thaw cycles. A spiking experiment was performed to determine if the sensitizer could be sufficiently recovered using standard procedures. The sensitizer was then extracted from the cell debris using DMSO, centrifuged, and the resulting supernatant was examined for fluorescence. Sensitizer concentration was determined by comparison to a standard curve. The results were expressed in μg / μg protein. Untreated monolayers were used to determine cell numbers. The treated cells at each time point were used to determine the protein concentration using the BCA assay. The results for these investigated photosensitizers are shown in Table 2. The results shown in the table are averages for three experiments at each time point.

As can be clearly seen for these compounds tested, the indium compound has a distinctly lower DC (50), independent of the functionality added to the chlorin.
(Light) value. In Vivo Assay of Photosensitizers for Tumors Female C3H / HeJ mice (8-9 weeks old) were subjected to trocar transplantation of BA mammary carcinoma in their hind paws. Animals with tumors about 5 mm in diameter were subjected to in vivo screening. For each novel photosensitizer, a group of at least three mice was used to adjust the dose of drug that, when treated with light of the appropriate wavelength, elicits a response as described in Table 3. confirmed. Generally, in this series, animals were administered sensitizers via the tail vein at 1 μM sensitizer / Kg body weight formulated in yolk phosphatase (EYP). At the end of the defined period, the animals were irradiated with light from a laser light source tuned to the activation wavelength of the sensitizer. The output density of the laser was set at 75 mW / cm ² and the total light irradiation was 200 J / cm ² . The spot size was 1 cm in diameter. Table 3 shows the results for each photosensitizer. Selected Kaplan-Meier curves for two different benzochlorin metal groups are
It is shown below. These curves are identified by their title.

[0045]

[Table 2]

[0046]

[Table 3]

[0047]

Embedded image

[0048]

Embedded image

The procedure of Examples 1-12 can be modified to produce other phototherapeutic compositions according to the present invention.
Each such composition essentially comprises a non-radioactive indium atom complexed with the internal nitrogen of a pyrrole core comprising at least two pyrroles. This improvement involves simply replacing the free base of another compound containing a pyrrole nucleus containing at least two pyrroles with the methylpyropheophorbide, benzoporphyrin derivative, i.e., Examples 1, 3, 4
, 5 and 6 with tetrakis (3-hydroxyphenyl) chlorin, octaethylbenzochlorin or the corresponding starting material of Example 7-12, or with a functionalized phthalocyanine, functionalized naphthocyanine, etc. Including substituting 4-t-butyl-1,2-dicyanobenzene of Example 2. Examples of compounds having a pyrrole core comprising at least two pyrroles and which can be substituted as described in the preceding section to produce ancillary compounds according to the invention are:
The names are listed in the following table and are defined by reference to FIGS. 1-58 that follow this table. Table 1 Macrocyclic Compounds Derived from Pyrrole (FIGURE 1) Natural or Synthetic Porphyrins and Derivatives (FIGURE 2) Natural or Synthetic Chlorins and Derivatives (FIGURE 3, 16, 17, 32-35 and 48-55) ) Bacteriochlorin and isobacteriochlorin (FIGURE 4, 5 and 36-4)
7) Phthalocyanine, naphthalocyanine and its derivatives (FIGURE 6, 7, 15, 18)
-21, 24, 26, 29, 30, 31 and 56) porphycenes and their derivatives (FIGURE 8) porphycyanines and their derivatives (FIGURE 9) pentaphyrins (pentaphyrins), sapphyrins and these Derivatives (FIGURE 10 and 11) Texaphyrins and their derivatives (FIGURE 12) Benzochlorin and its derivatives (FIGURE 13) Chlorophyll and its derivatives (FIGURE 14) Corroles (FIGURE 58)

[0050]

Embedded image

[0051]

Embedded image

[0052]

Embedded image

[0053]

Embedded image

[0054]

Embedded image

Derived from Table 1 on the types of photosensitizers and the literature outlined in FIGS. 1-57, which can be used in photodynamic therapy and imaging and are applicable to the insertion of indium into the central core of the sensitizer Examples and exemplifications are as follows: Dipyrromethenes: (FIGURE 1) Dipyrromethenes are widely used as intermediates in the synthesis of porphyrins (eg, “The Porphyrins”, D. Dolphin). Ed., Academic Press, 1978, V
ol. II, 215-223; Vol. I, Chapter IV, 101-234). The references in these books give actual experimental details. Metallo complexes can be produced by coordinating metal salts with these compounds (for example, AW Johnson, IT Kay, R. Price, KB Shaw, J. Che.
m. Soc. Perkin Trans I, 3416-3424, 1959; U.S. Patent No. 5,189,02 issued to SM Bloom, PP Garcia, JH Boyer,
9; LR Morgan, JH Boyer, U.S. Patent No. 5,446,157). As shown in FIGURE 1, these molecules can be synthesized such that a wide range of functionality can be directly attached to the basic dipyrromethene ring structure. Such functionality increases the ability to complex with water-soluble, lipophilic, biomolecules, such as antibodies or proteins, and increases the absorption wavelength of the molecule (by increasing the ability to complex the macrocycle). Available to Thus, these molecules can be used for photoactivated photochemistry or diagnostics.

Porphyrins (FIGURE 2): The synthetic routes for ubiquitous tetrapyrrole-based macrocycles containing 11 double bonds (excluding peripheral substituents) in the macrocycle ring system are described in Porphyrins and Me
talloporphyrins '', edited by KM Smith, published by Elsevier Publishing Company, NY, 197
5, Chapter 2, p29-55; Chapter 19, p778-785 and "The Porphyrins", edited by D. Dolphin,
Academic Press, 1978, Vol. The references in these books give actual experimental details. An extremely large number of porphyrin compounds have been synthesized. Since they are widely used by nature, a great deal of research on chemical modification of these compounds has been carried out ("The Porphyrins", D. Dolphin eds., Academic Pres.
s, 1978, Vol. I, p289-339). Numerous studies have been performed on the synthesis of porphyrins from monopyrrole ("The Porphyrins", edited by D. Dolphin, Academic
mic Press, 1978, Vol. I, Chapter 3, 85-100; Chapter 4, 101-234; Chapter 5, 235-26
4; Chapter 6, 265-288). Extremely valuable examples of such research are mono-, di-, and tri-
-And the synthesis of tetraphenylporphyrin ("The Porphyrins", D. Dolph
in Edition, Academic Press, 1978, Vol. I, Chapter 3, 88-90; Gunter, MJ, Mande
r, LN, J. Org. Chem., 1981, 46: 4792-4795). Such compounds can be widely functionalized because the aromatic ring can have various substituents or incorporate heteroatoms therein.

A porphyrin having a ring-forming aromatic ring at the β-pyrrole position can also be synthesized (TD Lash, C. Wijesinghe, AT Osuma, JR Patel, Tetrahedron Let
ters, 1997, 38 (12): 2031-2034). The aromatic ring has the effect of expanding the compounding range of the compound and improving its absorption and optical properties. Porphyrin-type compounds contain one or more heteroatoms in addition to nitrogen in the central porphyrin "core".
-Synthesized from a heterocyclic ring of member ring (for example, thiophene or furan) and pyrrole ("Porphyrins and Metalloporphyrins", edited by KM Smith, Elsevier Pu
blishing Company, NY, 1975, Chapter 18, 729-732). Such compounds can be similarly modified to produce highly functionalized derivatives. In addition, porphyrin dimers, trimers or oligomers have been synthesized in very large quantities (H. Meier
J. Chem. Soc. Chem. Commun., 1989, 923; GM Dubowchik et al., J. Chem. S.
oc.Chem.Commun., 1985, 904; RK Pandey et al., Tetrahedron Letters, 1992,
48: 8781; JL Sessler et al., Tetrahedron Letters, 1987, 28: 6569; A. Osaku et al.
Bull. Chem. Soc. Jpn., 1991, 64: 1213).

Chlorins: (FIGURE 3, 16, 17, 31-34, 47-54) Chlorins or hydroporphyrins (excluding peripheral substituents) have only 10 It is a porphyrin containing a heavy bond. The "reduction" of the porphyrin macrocycle has a significant effect on both the absorption profile of the macrocycle and the optical properties of the compound. Many naturally occurring chlorins can be extracted from plants, seaweeds or algae (eg, "Porphyrins and Metalloporphyrins", KM Smi
th Edition, Elsevier Publishing Company, NY, 1975, §H, p774-778). Also,
Simple chemical modifications to pheophorbide can yield pyropheophorbide, chlorin e6, purpurin 18 and other chlorin ring systems.
The synthetic route to chlorin macrocycles is outlined in the following literature: "Porphyrins and
Metalloporphyrins '', edited by KM Smith, published by Elsevier Publishing Company, NY,
1975, Chapter 2, p61-116; Chapter 19, p774-778; "The Porphyrins", edited by D. Dolphin,
Academic Press, 1978, Vol. II, p1-37, p131-143). The references in these books give actual experimental details. Considerable work has been done on the synthesis of chlorin derivatives from porphyrins.

Catalytic hydrogenation and hydroboration (HH Inhoffen et al., Tetrahedron Letters, 196
9, 1145), diimide reduction (HW Whitelock Jr. et al., J. Am. Chem. Soc., 1969, 9
1: 7585), osmium tetraoxide (R. Bonnett et al., J. Chem. Soc. Chem. Comm
un., 1989, 1822) and hydrogen peroxide (CK Chang, Biochemistry, 1971, 19: 1971).
), Alkali metal and electrochemical reduction (NS Hush et al., J. Am. Chem. Soc., 1967
, 89: 2976), aromatic radicals (GL Closs et al., J. Am. Chem. Soc., 1963, 85: 818
) Have all succeeded in producing chlorin from porphyrins. The use of light as a means of reduction has also been widely studied by several researchers. The reaction of vinylporphyrin with atomic oxygen is widely used for the production of chlorin (H.
H. Inhoffen et al., Ann. Chem., 1969, 730: 173; D. Brault et al., Photochem. Photob.
iol., 1988, 47: 151). Free base and metalloporphyrin, light and reducing agent (
For example, reaction with an amine or ascorbate also produces chlorin (Y. Harel
J. Am. Chem. Soc., 1977, 100: 6228; JH Fuhrhop et al., Tetrahedron Lette.
rs, 1970, 2815; DG Whitten et al., J. Am. Chem. Soc., 1971, 93: 2291).

The cyclization of porphyrins containing meso-acrylates is widely used in the production of perpurin derivatives (FIGURE 16 and 17) (AR Morgan et al., J. Org. Chem., 19
86, 51: 1347), while the acid cyclization of meso-acrolein porphyrin is widely used in the production of benzochlorin (FIGURE 13) (MGH Vincente et al., Tetrahe
dron Letters, 1990, 31: 1365; MJ Gunter et al., Tetrahedron, 1991, 47: 7853)
. Dielsophile addition of dienophile by vinyl-containing porphyrin
Widely used for the production of chlorin (FIGURE 49-54) (R. Grigg et al., Chem.
Commun., 1968, 697; HJ Callot et al., J. Chem. Soc. Perkin Trans., 1973, 1
VS Pangka et al., J. Org.Chem., 1986, 51: 1094; P. Yon-Hin et al., Tetrah
edron Letters, 1991, 32: 2875; P. Yon-Hin et al., J. Chem., 1992, 16: 527; AR
Morgan et al., J. Med. Chem., 1991, 34). Acetamide porphyrin is cyclized to
Chlorins can be produced via the intramolecular Vilsmeier reaction (GL Collier et al., J. Chem. Soc. C., 1969, 564). Recently, a chlorin analog of parpurin 18 based on purpurin 18 has been prepared which has a nitrogen atom in its cyclic "anhydrous" ring system (FIGURE 35, A or B = NR) (AN Kosyrev et al., Tetrahedr.
on Letters, 1997, 38: 3335).

Bacteriochlorins and isobacteriochlorins: (FIGURE 4, 5, 35-46)
B) Bacteriochlorins and isobacteriochlorins are tetrahydroporphyrins. These derivatives contain only nine double bonds in their macrocyclic ring system (including peripheral groups). "Double" reduction of the porphyrin nucleus at the pyrrole position has a significant effect on its absorption and optical properties.
Typically, bacteriochlorins absorb light in the range of 720-850 nm, while isobacteriochlorins absorb light in the range of 500-650 nm ("The Porphyrin
s ", D. Dolphin, eds., Academic Press, 1978, Vol. III, Chapter 1; references to these books provide actual experimental details). Examples of the synthesis of bacteriochlorins and isobacteriochlorins can be found in the following literature: HH Inho
ffen et al., Justus Leibigs Ann. Chem., 1967, 704: 188; H. Mittenzwei, Hoppe-S
eyler, s Z. Physiol. Chem., 1942, 275: 93; H. Brockmann Jr. et al., Arch. Micr.
obiol., 1972, 85: 123; JJ Katz et al., J. Am. Chem. Soc., 1972, 94: 7983; 199.
U.S. Pat.No. 5,648,485 issued to D. Dolphin et al. On Jul. 15, 7; September 1992
D. Dolphin et al., U.S. Pat.No. 5,149,708, issued on 22nd; HW Whitlock et al.,
J. Am. Chem. Soc., 1969, 91: 7485; HH Inhoffen et al., Tetrahedron Letters,
1972, 1115; HH Inhoffen et al., Tetrahedron Letters, 1969, 5145; JH Fuhrh
op et al., Tetrahedron Letters, 1970, 2815; A. Scherz et al., European Patent 0548,522 A
No. 5,650,292 to A. Scherz et al .; AN Kosyrev et al., Tetrahedron Lette
rs, 1997, 38: 3335.

In particular, osmium tetraoxide has been shown to be useful in the synthesis of β, β-dihydroxy-bacteriochlorin and isobacteriochlorin from chlorin (US Pat. No. 5,591,847 to RK Pandey et al.), And Acid rearrangement of these derivatives produced a number of bacteriochlorin derivatives. Treatment of porphyrins and chlorins with hydrogen peroxide has been used to produce bacteriochlorins and isobacteriochlorins (HH Inhoffen et al., Justus Liebigs
Ann. Chem., 1969, 725: 167). Diels-Alder addition of dienophiles with porphyrins containing two β-vinyl substituents is widely used to produce bacteriochlorins and isobacteriochlorins (R. Grigg et al., Chem.
Commun., 1968, 697; HJ Callot et al., J. Chem. Soc. Perkin Trans. I, 1424,
1973; P. Yn-Hin et al., Tetrahedron Letters, 1991, 32: 2875; AR Morgan et al., J
Med. Chem., 34, 1991).

Phthalocyanines and Naphthalocyanines: (FIGURE 6, 18, 21-24, 28-30) Phthalocyanines and their analogs are probably some of the most widely studied in the field of photodynamic therapy. It is also widely used as an optical recording medium. Therefore, the number of structurally different phthalocyanine derivatives is enormous.
Not only can the electronic spectrum and the peripheral functionality that alters the optical properties of the compound be varied, but the metallization of its macrocycle also results in an alteration of the optical properties. Further, the carbon in the aromatic ring can be replaced with a heteroatom (e.g., nitrogen, sulfur, phosphorus),
This substitution significantly changes the optical properties of the compound. Examples of literature describing the preparation of such compounds are as follows: "Phthalocyanines: Properties and Appl.
ications '', CC Leznoff et al., VCH Publishers Inc., 1989; `` The Phthalocyan
ines, FH Moser et al., CRC Press, Vol. I & II, 1983; "The Porphyrins",
D. Dolphin eds., Academic Press, 1978, Vol. I, Chapter 9, p. 374-380, references in these books give actual experimental details; AK Sobbi et al., J. Chem. So
c. Perkin Trans. 2, 1993, 481-488; JH Weber et al., Inorg. Chem., 1988, 192.
: 713; RP Linstead et al., J. Chem. Soc., 1950, 2975; M. as of November 24, 1992.
U.S. Patent No. 5,166,197 to E. Kenney et al .; ME Ke
U.S. Pat. No. 5,484,778 to P. Gregory et al., issued Jan. 16, 1996. Numerous dinuclear phthalocyanines / naphthalocyanines have been synthesized which share a common benzene or naphthalene ring (J. Yang et al., Tetrahedron Letters, 1993, 34: 5223; N. Kobayashi et al.
Chemistry Letters, 1994, 1813).

Azoporphyrins: (FIGURE 18, 20, 21, 30, 55) Porphyrins containing at least one meso-nitrogen bonding atom are called azoporphyrins. The number of meso-nitrogen bonding atoms can range from one to four. Phthalocyanines and naphthalocyanines can be considered to be tetraazoporphyrins with extended conjugation due to ring-forming benzene or naphthalene rings. The synthesis of mono-, di-, tri- and tetraazoporphyrin analogs is described in;
Porphyrins ", edited by D. Dolphin, Academic Press, 1978, Vol. I, Chapter 9, p. 365
-388; "Phthalocyanines: Properties and Applications", CC Leznoff et al.,
VCH Publishers Inc., 1989; "The Phthalocyanines", FH Moser et al., CRC Pr
ess, Vol. I & II, 1983. The references in these books give actual experimental details. The synthesis of a series of tetrabenzotriazoporphyrins and tetranaphthotriazoporphyrins has recently been published (YH, Tse et al., Can. J. Chem.
, 1993, 71: 742), and obviously chemistry typical of phthalocyanine and porphyrin chemistry is applicable to these compounds, thus introducing heteroatoms into the ring-forming benzene and naphthalene rings. it can.

Non-symmetric benzonaphthoporphyrazines (FIGURE 25-27, 57) Non-symmetric tetraazoporphyrins having both benzene and naphthalene ring forming units in the macrocyclic ring system are vaguely known as benzonaphthoporphyrazines. being called. The synthesis of these derivatives has been carried out using classical phthalocyanine synthesis methods, but mixed aromatic dinitrile has been used (U. Michelsen et al., Photoche
m. Photobiol., 1996, 64: 694; Canadian Patent No. 2,130,853 to SV Kudrevich et al., filed on 25/8/1994). References relating to the synthesis of these macrocycles can be found in "Phthaloc
yanines: Properties and Applications '', CC Leznoff et al., VCH Publishers
Inc., 1989; "The Phthalocyanines", FH Moser et al., CRC Press, Vol. I &
II, 1983.

Texaphyrins: (FIGURE 12) Texaphyrins are “expanded porphyrin” macrocycles derived from tripyrrole dimethene, the central core of which is larger than the porphyrin central core. Reaction of diformyltripyran with a functionalized aromatic diamine in the presence of a metal gives the functionalized, metallated texaphyrin (JL Sessle
R. et al., U.S. Pat.No. 5,252,720; JL Sessler et al., U.S. Pat.No. 4,935,498; D. Ma
gda et al., US Pat. No. 5,567,687). Pentaphyrins and Sapphyrins: (FIGURE 10, 11) Sapphirins and pentaphyrins are completely conjugated macrocycles, which have five pyrrole units. The structural similarities between these saphirins and pentaphyllins are described in "Porphyrins and Metalloporphyrins", edited by KM Smith, Elsevi
er, Chapter 18, p.750-751; "The Porphyrins", D. Dolphin, Academic Press
Publishing, NY, Chapter 10, p.351-356; Broadherst et al., J. Chem. Soc. Perkin Trans. I,
1972, 2111; JL Sessler et al., US Pat. No. 5,543,514.

Porphycenes: (FIGURE 8) Porphycenes are isomeric analogues of porphyrins with 11 double bonds in the macrocyclic core, formally derived by simple recombination of the pyrrole and methine moieties. It is. Synthetic routes for functionalized porphycenes are outlined in the following references: E. Vogel et al., US Pat. No. 5,409,900; E. Vogel et al., US Pat.
U.S. Pat.No. 5,244,671; E. Vogel et al., U.S. Pat.
U.S. Pat.No. 5,637,608; E. Vogel et al., U.S. Pat.
J. Am. Chem. Soc., 1992, 114; N. Jux et al., Angew. Che.
m. Int. Ed. Engl., 1990, 29: 1385.

Corroles: (FIGURE 57) Corroles contain an aromatic 18-electron chromophore. The synthesis and structural modifications (e.g., N-alkylation) of these compounds are described in "The Porphyrins", edited by D. Dolphin, Academic
Press, 1978, Vol. I, Chapter 9, pages 357-363 and "Porphyrins and Metallopor
phyrins '', edited by KM Smith, published by Elsevier Publishing Company, NY, 1975, Chapter 18,
This is discussed in detail in pages 730-749. Various changes and modifications can be made to the specific details of the invention, as described above, and as described in the examples below, and, in an essential part of the invention, the invention is According to the composition, the composition essentially comprises a non-radioactive indium atom complexed with an internal nitrogen atom of a pyrrole core having at least two pyrroles, provided that the porphyrin in a completely unsaturated state is Has the structure:

[0069]

Embedded image

Where R1, R2, R4 and R6 are methyl, R8, R10, R11 and R12 are hydrogen, and R7 and R8 are CH ₂ CH ₂ COR13 (where R13 is an amino acid From which H is removed), and

[0071]

Embedded image

(Where R 1 is CH (OH) Me, R is an alkyl group, and R ² is a moiety formed by removing H from an amino acid). Preferably, the present invention relates to a composition comprising essentially non-radioactive indium atoms, complexed with the internal nitrogen of the tetrapyrrole core, except for the porphyrins which are completely unsaturated as defined above. . Non-radioactive indium atoms, complexed with the internal nitrogen of a photosensitive compound having a dihydro or tetrahydrotetrapyrrole core, are another preferred composition of the present invention.

Other preferred compounds of the invention are those having the structures shown in FIGS. 1-58 above. Specifically, one preferred group is one having the structure shown in FIG. 2 wherein each of R1 to R12 is H, halogen, alkyl, cycloalkyl (number of carbon atoms)
3-6), aryl, vinyl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR12R12, CN, OH, OR12, CHO, (C
_{H 2) n OH, (CH} 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR12,} (CH 2) n OR12 ( where, n =
1, 2, 3, 4, and R12 are the following functional groups 100,000 _{daltons), (CH 2) n CO} 2 R12 (
Here, R is H, a physiologically acceptable salt, alkyl (1 to 6 carbon atoms), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, a is _{3,4), (CH 2) n} CONHR12, (CH 2) n CON (R12) 2, CO 2 R12 ( wherein, R12 is the following functional groups 100,000 daltons), SR12 (wherein, R12 Is 10
0000 Dalton or less of a functional _{group), SO 3 H, SO 3} R12, SO 2 NHR12, SO 2 N (R12) 2, SO 2 N (R12) 3 + X - ( wherein, R12 below 100,000 Daltons X is a charge-balancing ion). Z is halogen, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or a functional group of up to 100,000 daltons, protein or biomolecule, provided that the pyrrole core is completely unsaturated. In some cases, the above exclusions apply. Yet another preferred group has the structure:

[0074]

Embedded image

Here, each of R 1 to R 14 is H, halogen, alkyl, cycloalkyl (C 3 to C 14)
6), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, _{ester, C (X) 2 C (} X) 3 ( wherein, X is halogen atom),
NR15R15, CN, OH, OR15, CHO, COCH 3, (CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR15,} (CH 2) n OR15 ( here, n = 1, 2, 3, 4, and R15 are the following functional groups 100,000 _{daltons), (CH 2) n CO} 2 R15 ( wherein, R15 is H, physiologically acceptable salts, Alkyl (1-6 carbon atoms), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4
_{), (CH 2) n CONHR15} , (CH 2) n CON (R15) 2, CO 2 R15 ( wherein, R15 is the following functional groups 100,000 daltons), SR15 (wherein, R15 below 100,000 Daltons Functional group),
_{SO 3 H, SO 3 R15,} SO 2 NHR15, SO 2 N (R15) 2, SO 2 N (R15) 3 + X - ( wherein, R15 is the following functional groups 100,000 daltons, and X is a charge balancing an ion in a), M is a mixture of in ^{1 13,} in ¹¹⁵ or an in ¹¹³ and an in ^115, Z is a halogen, acetate groups, OH,
Alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or a functional group, protein or biomolecule of up to 100,000 daltons. M in the above formula may be Pd, Sn, Pt, Al, Ru, Ga. Another preferred group has the following structure:

[0076]

Embedded image

Here, R 1 to R 4 are SO ₃ H (or a salt thereof), SO ₂ NHR5, CO ₂ H (or a salt thereof), CON
HR5, OH, OR5 (where R5 is an alcohol or ether containing group), amide, N
(CH ₃ ) ₂ , selected from N (Et) ₂ , M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ , Z is halogen, acetate, OH, and M in the above formula is , Pd, Sn, Pt, Al, Ru
, Ga. Another preferred group has the following structure:

[0078]

Embedded image

Here, each of A, B, C, D and E is C, N, N ⁺ R (R is a charged or uncharged alkyl group) or a combination thereof, and M is In ¹¹³ a mixture of an in ¹¹⁵ or an in ^{11 3} and an in ^115, Z is a halogen, acetate groups are OH, M in the above formulas, Pd, Sn, Pt, Al , Zn, Ru, even Ga Good. Yet another preferred group has the structure:

[0080]

Embedded image

Here, each of R 1 to R 16 is H, halogen, alkyl, cycloalkyl (C 3
6), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, _{ester, CH = CHCH 2 N (CH} 3) 2, CH = CHCH 2 N + (CH 3) 3 X - (X is C (X) ₂ C (X) ₃ (where X is a halogen atom), NR1
7R17, CN, OH, OR17, CHO, COCH 3, CH (OR17) CH 3, (CH 2) n OH, (CH 2) n SH, (CH 2) n O
- _{alkoxy, (CH 2) n SR17,} (CH 2) n OR17 ( where, n = 1, 2, 3, 4, and R17 is 1
00000 Dalton or less of a functional _{group), (CH 2) n CO} 2 R17 ( wherein, R17 is H, physiologically acceptable salts, alkyl (1-6 carbon atoms), aryl, substituted aryl, alkenyl , Substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2,
3, 4), (CH ₂ ) _n CONHR17, (CH ₂ ) _n CON (R17) ₂ , CO ₂ R17, CONHR17, CONR17R17
, SR17 (wherein, R17 is the following functional groups 100,000 _{daltons), SO 3 H, SO 3} R17, SO 2 NHR17, SO 2 N (R17) 2, SO 2 N (R17) 3 + X - ( wherein in, R17 is the following functional groups 100,000 daltons, and X is a is) a charge balancing ion, M is a mixture of an in ^113, an in ¹¹⁵ or an in ^{1 13} and an in ^115, Z is a halogen, acetate roots , OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkyne or a functional group of up to 100,000 daltons, protein or biomolecule. Yet another preferred group has the structure:

[0082]

Embedded image

Here, each of R 1 to R 4 represents SO ₃ H (or a salt thereof), SO ₂ NHR5, CO ₂ H (or a salt thereof), C 2
ONHR5, OH, OR5 (wherein, R5 is an alcohol or ether-containing group), amido, N (CH ₃₎ a _{2, N (Et) 2,} M is an In ^113, an In ¹¹⁵ or an In ¹¹³ and an In ¹¹⁵ Wherein Z is halogen, acetate, OH, and M may be Pd, Sn, Pt, Al, Zn, Ru, Ga. Yet another preferred group has the structure:

[0084]

Embedded image

Where each AE is C, N, N ⁺ R (R is a charged or uncharged alkyl group) and M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ Wherein Z is halogen, acetate, OH, and M may be Pd, Sn, Pt, Al, Zn, Ru, Ga. Yet another group has the following structure:

[0086]

Embedded image

Here, each of R 1 to R 10 is H, halogen, alkyl, cycloalkyl (C 1 to C 10)
6), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted
Alkynyl, amide, ester, CH = CHCH_TwoN (CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(X is
(Balanced ion), C (X)_TwoC (X)_Three(Where X is a halogen atom), NR11R
11, CN, OH, OR11, CHO, COCH_Three, CH (OR11) CH_Three, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-
Alkoxy, (CH_Two)_n SR11, (CH_Two)_n OR11 (where n = 1, 2, 3, 4, and R11 is 10
0000 Dalton or less), (CH_Two)_n CO_TwoR11 (where R11 is H, physiologically
Acceptable salts, alkyl (1-6 carbon atoms), aryl, substituted aryl, alkenyl
, Substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2,
3, 4), (CH_Two)_nCONHR11, (CH_Two)_nCON (R11)_Two, CO_TwoR11, CONHR11, CONR11R11
, SR11 (where R11 is a functional group of 100000 Dalton or less), SO_ThreeH, SO_ThreeR11, SO_Two NHR11, SO_TwoN (R11)_Two, SO_ThreeN (R11)_Three ⁺X^-(Where R11 is a functional group of 100,000 daltons or less
And X is a charge-balanced ion) and M is In¹¹³, In¹¹⁵Or In^{1 13} And In¹¹⁵Wherein Z is halogen, acetate, OH, alkyl, aryl
, Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl
Or a functional group, protein or biomolecule of up to 100,000 daltons. M may be Pd, Sn, Pt, Al, Zn, Ru, Ga. Another group of compounds has the structure immediately above, where R1, R2, R6, R7 each
, CO_TwoH (or its salt), or CO_TwoR11 (where R11 is an alkyl or aryl group
R3 and R8 are each methyl or ethyl and R4, R5, R9, R
10 each is methyl, ethyl, alkyl, CH_TwoCH_TwoCO_TwoH (or its salt), or CH_TwoCH _Two CO_TwoR11, wherein R11 is alkyl or aryl, and M is In¹¹³, In^{11 Five} Or In¹¹³And In¹¹⁵Wherein Z is halogen, acetate or OH
, M may be Pd, Sn, Pt, Al, Zn, Ru, Ga. Yet another group of compounds has the structure:

[0088]

Embedded image

Here, each of R 1 to R 10 is H, halogen, alkyl, cycloalkyl (C 3 to C
6), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, _{ester, CH = CHCH 2 N (CH} 3) 2, CH = CHCH 2 N + (CH 3) 3 X - (X is a charge C (X) ₂ C (X) ₃ (where X is a halogen atom), NR11R
11, CN, OH, OR11, CHO, COCH 3, CH (OR11) CH 3, (CH 2) n OH, (CH 2) n SH, (CH 2) n O-
Alkoxy, (CH ₂ ) _n SR 11, (CH ₂ ) _n OR 11 (where n = 1, 2, 3, 4, and R 11 is 10
0000 Dalton or less of a functional _{group), (CH 2) n CO} 2 R11 ( wherein is H, physiologically acceptable salts R11, alkyl (1-6 carbon atoms), aryl, substituted aryl, alkenyl , Substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2,
3, 4), (CH ₂ ) _n CONHR11, (CH ₂ ) _n CON (R11) ₂ , CO ₂ R11, CONHR11, CONR11R11
, SR11 (wherein, R11 is 100,000 daltons or less functional _{groups), SO 3 H, SO 3} R11, SO 2 NHR11, SO 2 N (R11) 2, SO 3 N (R11) 3 + X - ( wherein in, R11 is the following functional groups 100,000 daltons, and X is a is) a charge balancing ion, M is a mixture of an in ^113, an in ¹¹⁵ or an in ^{1 13} and an in ^115, Z is a halogen, acetate roots , OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or a functional group, protein or biomolecule of up to 100,000 daltons. Another group of compounds has the following structure:

[0090]

Embedded image

Here, each of R1 to R10 is H, halogen, alkyl, cycloalkyl (3 to
6), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, _{ester, CH = CHCH 2 N (CH} 3) 2, CH = CHCH 2 N + (CH 3) 3 X - (X is a charge C (X) ₂ C (X) ₃ (where X is a halogen atom), NR11R
11, CN, OH, OR11, CHO, COCH 3, CH (OR11) CH 3, (CH 2) n OH, (CH 2) n SH, (CH 2) n O-
Alkoxy, (CH ₂ ) _n SR 11, (CH ₂ ) _n OR 11 (where n = 1, 2, 3, 4, and R 11 are 100
000 daltons or less functional _{groups), (CH 2) n CO} 2 R11 ( wherein is H, physiologically acceptable salts R11, alkyl (1-6 carbon atoms), aryl, substituted aryl, alkenyl , Substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3,
, 4), (CH ₂ ) _n CONHR11, (CH ₂ ) _n CON (R11) ₂ , CO ₂ R11, CONHR11, CONR11R11,
SR11 (wherein, R11 is the following functional groups 100,000 _{daltons), SO 3 H, SO 3} R11, SO 2 NH
_{R11, SO 2 N (R11)} 2, SO 3 N (R11) 3 + X - ( wherein, R11 is the following functional groups 100,000 daltons, also X is a charge balancing ion) and, M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ , wherein Z is halogen, acetate, OH, alkyl, aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or a functional group up to 100000 Dalton, protein or biomolecule, M is Pd, Sn, P
It may be t, Al, Zn, Ru, Ga. Another group of compounds has the following structure:

[0092]

Embedded image

Here, each of R1, R2, R6, and R7 is CO ₂ H (or a salt thereof) or CO ₂ R11 (here, R11
A is an alkyl or aryl group), each R3 and R8 is methyl or ethyl, R4, R5, R9, R10 each are methyl, ethyl, alkyl, CH ₂ CH ₂ CO ₂ H
(Or a salt thereof), or CH ₂ CH ₂ CO ₂ R11 (wherein, R11 is alkyl or aryl which is) is, M is a mixture of an In ^113, an In ¹¹⁵ or an In ¹¹³ and an In ^115, Z is a halogen , Acetate or OH, and M may be Pd, Sn, Pt, Al, Zn, Ru, Ga. Yet another group of compounds has the structure:

[0094]

Embedded image

Here, each of R 1 to R 14 is H, halogen, alkyl, cycloalkyl (C 3 to C 14)
6), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, _{ester, CH = CHCH 2 N (CH} 3) 2, CH = CHCH 2 N + (CH 3) 3 X - (X is a charge C (X) ₂ C (X) ₃ (where X is a halogen atom), NR15R
15, CN, OH, OR15, CHO, COCH 3, CH (OR15) CH 3, (CH 2) n OH, (CH 2) n SH, (CH 2) n O-
_{Alkoxy, (CH 2) n SR15,} (CH 2) n OR15 ( where, n = 1, 2, 3, 4, and R15 are 100
000 daltons or less functional _{groups), (CH 2) n CO} 2 R15 ( wherein, R15 is H, physiologically acceptable salts, alkyl (1-6 carbon atoms), aryl, substituted aryl, alkenyl , Substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3
, 4), (CH ₂ ) _n CONHR15, (CH ₂ ) _n CON (R15) ₂ , CO ₂ R15, CONHR15, CONR15R15,
SR15 (wherein, R15 is 100,000 daltons or less functional _{groups), SO 3 H, SO 3} R15, SO 2 NH
_{R15, SO 2 N (R15)} 2, SO 3 N (R15) 3 + X - ( wherein, R15 is the following functional groups 100,000 daltons, also X is a charge balancing ion) and, M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ , wherein Z is halogen, acetate, OH, alkyl, aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or a functional group, protein or biomolecule of up to 100,000 daltons. Yet another group of compounds has the structure:

[0096]

Embedded image

Wherein each of R1, R2, R3, R4, R8, R9, R10, R11 is CN, each of R5 and R12 is methyl or ethyl, and each of R6, R7, R13 and R14 is methyl , ethyl, _{alkyl, CH 2 CH 2 CO 2 H} ( or a salt thereof), or CH ₂ CH ₂ CO ₂ R15 (wherein, R15 is alkyl or aryl which is) is, M is in ^113, in ¹¹⁵ or in A mixture of ¹¹³ and In ¹¹⁵ , wherein Z is halogen, acetate or OH, and M is Pd, Sn, Pt, Al, Zn,
Ru or Ga may be used. Another group of compounds has the following structure:

[0098]

Embedded image

Here, each of R1 to R8 is H, halogen, alkyl, cycloalkyl (having 3 to 6 carbon atoms).
), Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, _{ester, CH = CHCH 2 N (CH} 3) 2, CH = CHCH 2 N + (CH 3) 3 X - (X is a charge balancing Ion), C (X) ₂ C (X) ₃ (where X is a halogen atom), NR9R9
, CN, OH, OR9, CHO , COCH 3, CH (OR9) CH 3, (CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR9,} ( CH _{2) n} OR9 (wherein, n = 1, 2, 3, 4, and R9 are the following functional groups 100,000 _{daltons), (CH 2) n CO} 2 R9 ( wherein, R9 is H, physiological Salts, alkyl (1-6 carbon atoms), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4)
, (CH ₂ ) _n CONHR9, (CH ₂ ) _n CON (R9) ₂ , CO ₂ R9, CONHR9, CONR9R9, SR9 (where R9 is
100,000 daltons or less functional _{groups), SO 3 H, SO 3} R9, SO 2 NHR9, SO 2 N (R9) 2, SO 3 N
(R9) ₃ ⁺ X ^- (wherein, R9 is the following functional groups 100,000 daltons, also X is a charge balancing ion) and, M is a mixture of an In ^113, an In ¹¹⁵ or an In ¹¹³ and an In ¹¹⁵ And Z is halogen, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or a functional group of up to 100,000 daltons, protein or biomolecule. Yet another group of compounds has the structure:

[0100]

Embedded image

Where each of R1 and R5 is alkyl or aryl, each of R2 and R6 is methyl or ethyl, and each of R7, R8, R3 and R4 is methyl, ethyl, alkyl, CH ₂ CH ₂ CO ₂ H (or a salt thereof), or CH ₂ CH ₂ CO ₂ R9 (wherein, R9 is alkyl or aryl which is) is, M is a mixture of an in ^113, an in ¹¹⁵ or an in ¹¹³ and an in ^115, Z Is halogen, acetate or OH, and M may be Pd, Sn, Pt, Al, Zn, Ru, Ga. Yet another group of compounds has the structure:

[0102]

Embedded image

Here, each of R 1 to R 14 is H, halogen, methyl, ethyl, alkyl, cycloalkyl (3 to 6 carbon atoms), aryl, substituted aryl, alkenyl, substituted alkenyl,
Alkynyl, substituted alkynyl, amide, _{ester, C (X) 2 C (} X) 3 ( wherein, X is halogen atom), NR15R15, CN, OH, OR15, CHO, COCH 3, CH (OR15) CH 3 , (CH ₂ ) _n OH
_{, (CH 2) n SH,} (CH 2) n O- _{alkoxy, (CH 2) n SR15,} (CH 2) n OR15 ( where, n = 1, 2, 3
, 4 and R15 are the following functional groups 100,000 _{daltons), (CH 2) n CO} 2 R15 ( wherein, R1
4 is H, a physiologically acceptable salt, alkyl (1 to 6 carbon atoms), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4 ), (CH ₂ ) _n CONHR15, (CH ₂ ) _n CON (R15) ₂ , CO ₂ R15, CONHR
15, CONR15R15, SR15 (where R15 is a functional group of 100000 dalton or less, and n
= 1,2,3,4 _{is), SO 3 H, SO 3} R15, SO 2 NHR15, SO 2 N (R15) 2, SO 3 N (R15) 3 + X - ( wherein, R15 100000 Daltons Wherein X is a charge-balancing ion), M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ , and Z is halogen, acetate, OH, alkyl, aryl, Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl or a functional group, protein or biomolecule of up to 100,000 daltons. M may be Pd, Sn, Pt, Al, Zn, Ru, Ga. Yet another group of compounds has the structure:

[0104]

Embedded image

Here, each of R 1 to R 8 is ethyl or methyl, and R 9 is CH ₃ , SO ₂ NH (CH ₂ CH ₂ O) _n CH ₃ (n = 1 to 1000), SO ₂ N ((CH _{2 2} CH ₂ O) _n CH ₃ ) ₂ (n = 1 to 1000), SO ₂ NH (CH ₂ ) _n OH (n = 1 to 1000), CH ₃ , SO ₂ N ((CH ₂ CH ₂ ) _n OH ) ₂ (n = 1 to 1000), SO ₂ NC ((N (CH ₃ ) ₂ ) ₂ , SO ₂ NH (CH ₂ ) _n N (CH ₃ ) ₂ (n =
1 to 1000), SO ₂ NH (CH ₂ ) _n SH (n = 1 to 1000), SO ₂ NHC (CH ₂ CH ₂ OH) ₃ , SO ₂ NHCH ₂ CO ₂ H (or salt thereof), SO ₂ NH (CH ₂ ) _n CH (NH ₂ ) CO ₂ H (or a salt thereof) (n = 1 to 5), SO ₂ NHCH ₂ CO ₂ R10 (R10 is an alkyl or aryl), SO ₂ NH (CH ₂ ) _n CH (NH ₂ ) CO ₂ R 10 (R 10 is alkyl or aryl) (n = 1 to 5), and M is In ¹¹³ , In ¹¹⁵ or In ¹¹³ and I
a mixture of n ¹¹⁵ , Z is halogen, acetate, OH, M is Pd, Sn, Pt, Al,
Zn, Ru, and Ga may be used. Yet another group of compounds has the structure:

[0106]

Embedded image

Here, each of R 1 to R 8 is ethyl or methyl, and R 9 is CH ₂ CO ₂ NH (CH ₂ CH ₂ O) _n CH ₃ (
n = 1 ~ 1000), CH ₂ CO ₂ N ((CH ₂ CH ₂ O) _n CH ₃ ) ₂ (n = 1 ~ 1000), CH ₂ CO ₂ NH (CH ₂ ) _n OH (n = 1 ~ 1000
), CH ₂ CO ₂ N ((CH ₂ CH ₂ ) _n OH) ₂ (n = 1 to 1000), CH ₂ CO ₂ NC ((N (CH ₃ ) ₂ ) ₂ , CH ₂ CO ₂ NH- (CH ₂ ) _n N (CH ₃ ) ₂ (n = 1 ~ 1000), CH ₂ CO ₂ NH (CH ₂ ) _n SH (n = 1 ~ 1000), CH ₂ CO ₂ NHC- (CH ₂ CH ₂ OH) ₃ ,
CH ₂ CO ₂ NHCH ₂ CO ₂ H (or salt thereof), CH ₂ CO ₂ NH (CH ₂ ) _n CH (NH ₂ ) CO ₂ H (or salt thereof)
(n = 1 ~ 5), CH 2 CO 2 NHCH 2 CO 2 R10 (R10 is alkyl, aryl), CH ₂ CO ₂ NH (
_{CH 2) n CH (NH 2} ) CO 2 R10 (R10 is alkyl, aryl) and (n = 1 ~ 5), M is I
n ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ , wherein Z is halogen, acetate, OH
And M may be Pd, Sn, Pt, Al, Zn, Ru, Ga. Yet another group of compounds has the structure:

[0108]

Embedded image

Here, each of R1 to R8 is H, halogen, alkyl, cycloalkyl (having 3 to 6 carbon atoms).
), Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted
Alkynyl, amide, ester, C (X)_TwoC (X)_Three(Where X is a halogen atom),
NR9R9, CN, OH, OR9, CHO, COCH_Three, (CH_Two)_nOH, (CH_Two)_nSH, CH (OR9) CH_Three, (CH_Two)_nO
-Alkoxy, (CH_Two)_nSR9, (CH_Two)_nOR9 (where n = 1, 2, 3, 4, and R9 are
), (CH_Two)_nCO_TwoR9 (where R9 is H, physiologically acceptable
Salt, alkyl (1-6 carbon atoms), aryl, substituted aryl, alkenyl, substituted
Lucenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4
), (CH_Two)_nCONHR9, (CH_Two)_nCON (R9)_Two, CO_TwoR9, CONHR9, CONR9R9, SR9 (where R9
Is a functional group of 100000 Dalton or less), SO_ThreeH, SO_ThreeR9, SO_TwoNHR9, SO_TwoN (R9)_Two, SO _Two N (R9)_Three ⁺X^-(Where R9 is a functional group of 100,000 daltons or less and X is charge fishing
M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵In a mixture of
Yes, Z is halogen, acetate, OH, alkyl, aryl, substituted aryl, alk
Nyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule
Or a functional group of 100,000 daltons or less. M is Pd, Sn, Pt, Al, Zn, Ru, Ga
It may be. Yet another group of compounds has the structure:

[0110]

Embedded image

Here, each of R1 to R17 is H, halogen, alkyl, cycloalkyl (having 3 to
6), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted
Alkynyl, amide, ester, C (X)_TwoC (X)_Three(Where X is a halogen atom),
NR18R18, CN, OH, OR18, CHO, COCH_Three, (CH_Two)_nOH, (CH_Two)_nSH, CH (OR18) CH_Three, (CH _Two )_nO-alkoxy, (CH_Two)_nSR18, (CH_Two)_nOR18 (where n = 1, 2, 3, 4, and R5 is 10
0000 Dalton or less), (CH_Two)_nCO_TwoR18 (where R18 is H,
Salts, alkyl (1-6 carbon atoms), aryl, substituted aryl, alkenyl
, Substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3,
, 4), (CH_Two)_nCONHR18, (CH_Two)_nCON (R18)_Two, CO_TwoR18, CONHR18, CONR18R18,
SR18 (where R18 is a functional group of 100000 Dalton or less), SO_ThreeX, SO_ThreeR18, SO_TwoNH
R18, SO_TwoN (R18)_Two, SO_ThreeN (R18)_Three ⁺X^-(Where R18 is a functional group of 100,000 daltons or less
And X is a charge-balanced ion) and M is In¹¹³, In¹¹⁵Or In¹¹³ And In¹¹⁵Wherein Z is halogen, acetate, OH, alkyl, aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
It is a protein or biomolecule or a functional group of 100,000 daltons or less. M is Pd or
May be Ga. Yet another group of compounds has the structure:

[0112]

Embedded image

Here, each of R1 to R24 is H, halogen, alkyl, cycloalkyl (having 3 to
6), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted
Alkynyl, amide, ester, C (X)_TwoC (X)_Three(Where X is a halogen atom),
NR25R25, CN, OH, OR25, CHO, COCH_Three, (CH_Two)_nOH, (CH_Two)_nSH, CH (OR25) CH_Three, (CH _Two )_n O-alkoxy, (CH_Two)_n SR25, (CH_Two)_n OR25 (where n = 1, 2, 3, 4, and R25
Is a functional group of 100000 Dalton or less), (CH_Two)_nCO_TwoR25 (where R25 is H, physiological
Salts, alkyl (1-6 carbon atoms), aryl, substituted aryl, alk
Nyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2
, 3, 4), (CH_Two)_n CONHR25, (CH_Two)_n CON (R25)_Two, CO_TwoR25, CONHR25, CONR25
R25, SR25 (where R25 is a functional group of 100000 Dalton or less), SO_ThreeH, SO_ThreeR25,
SO_TwoNHR25, SO_TwoN (R25)_Two, SO_TwoN (R25)_Three ⁺X^-(Where R25 is a government of 100,000 daltons or less
And X is a charge-balanced ion) and M is In¹¹³, In¹¹⁵Also
Is In¹¹³And In¹¹⁵A, B, C, D, E, F are C, N, O +, O, S, Te,
P, N⁺(R25) X^-(Where R25 is a functional group of 100,000 daltons or less, and X is
Z is halogen, acetate, OH
, Alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl
, Substituted alkynyls, proteins or biomolecules or functionalities up to 100,000 daltons
Group. M may be Pd or Ga. Yet another group of compounds has the structure:

[0114]

Embedded image

Here, each of R1 to R5 is CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^- (Where X is a charge-balanced ion), C (X)_TwoC (X)_Three(Where X is halogen
Atom), CHO, COCH_Three, CO_TwoH, CO_TwoR6, CONHR7, CH = CHCHO, CH_TwoY (where Y is
H, halogen, OH, OR6, or a functional group of 100,000 daltons or less), CH = CHC
H_TwoOH, CH = CHCH_TwoOR6, CH (OH) CH_Three, CH (OR6) CH_Three, H, halogen, alkyl, shik
Loalkyl (1-6 carbon atoms), aryl, substituted aryl, alkenyl, substituted al
Kenyl, alkynyl, substituted alkynyl, amide, ester, NR6R6, CN, OH, OR6
, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_n O-alkoxy, (CH_Two)_n SR6, (CH_Two)_nOR6 (where
, N = 1, 2, 3, 4, and R6 are functional groups of 100000 Dalton or less), (CH_Two)_nCO_TwoR6 (
Here, R is H, a physiologically acceptable salt, alkyl (1 to 6 carbon atoms), aryl
, Substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkyl
N, and n = 1, 2, 3, 4), (CH_Two)_n CONHR6, (CH_Two)_n CON (R6)_Two, CO _Two R6, CONHR6, CONR6 R6, SR6 (where R6 is a functional group of 100000 Dalton or less)
, SO_ThreeH, SO_ThreeR6, SO_TwoNHR6, SO_TwoN (R6)_Two, SO_TwoN (R6)_Three ⁺X^-(Where R6 is 100,000 dalts
X is a charge-balancing ion), and X is O, 2H
, (H, OH), S, (H, OR6) or a ketone protecting group, wherein M is In¹¹³, In¹¹⁵Or In^{1 13} And In¹¹⁵Wherein Z is halogen, acetate, OH, alkyl, aryl
, Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
It is a protein or biomolecule or a functional group of 100,000 daltons or less. M is Pd, Sn
, Pt, Al, Zn, Ru, Ga. Yet another group of compounds has the structure:

[0116]

Embedded image

Where R 1 is CH = CH ₂ , CHO, Et, COCH ₃ , R 2 is CO ₂ CH ₃ , CO ₂ H, amide, R 3 and R 4 are H, and R 5 is CH ₃ X is O, M is In ¹¹³ , In ¹¹⁵ or I
a mixture of n ¹¹³ and In ¹¹⁵ , Z is halogen, acetate or OH, and M is also Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho, La , Lu, Mo, Nd, Pb,
Pd, Pr, Pt, Rh, Sb, Sc, Sm, Sn, Pt, Ru, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb
, Zn or Zr, preferably Pd, Sn, Pt, Al, Zn, Ru, Ga. Yet another group of compounds has the following structural formula:

[0118]

Embedded image

Here, R1-R6 are each CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^- (Where X is a charge-balanced ion), C (X)_TwoC (X)_Three(Where X is halogen
Atom), CHO, COCH_Three, CO_TwoH, CO_TwoR7, CONHR7, CH = CHCHO, CH_TwoY (where Y is
H, halogen, OH, OR7, or a functional group of 100,000 daltons or less), CH = CHC
H_TwoOH, CH = CHCH_TwoOR7, CH (OH) CH_Three, CH (OR7) CH_Three, H, halogen, alkyl, cyclo
Alkyl (1-6 carbon atoms), aryl, substituted aryl, alkenyl, substituted alk
Nil, alkynyl, substituted alkynyl, amide, ester, NR7R7, CN, OH, OR7,
(CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_n O-alkoxy, (CH_Two)_n SR7, (CH_Two)_nOR7 (where
n = 1, 2, 3, 4, and R7 are functional groups of 100,000 daltons or less), (CH_Two)_nCO_TwoR7 (this
Here, R is H, a physiologically acceptable salt, alkyl (1 to 6 carbon atoms), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl
And n = 1, 2, 3, 4), (CH_Two)_n CONHR7, (CH_Two)_n CON (R7)_Two, CO_TwoR
7, CONHR7, CONR7 R7, SR7 (where R7 is a functional group of 100000 Dalton or less), S
O_ThreeH, SO_ThreeR7, SO_TwoNHR7, SO_TwoN (R7)_Two, SO_TwoN (R7)_Three ⁺X^-(Where R7 is 100000 Dalton
Where X is a charge-balancing ion) and M is In¹¹³, In ¹¹⁵ Or In¹¹³And In¹¹⁵Z is halogen, acetate, OH, alkyl
, Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted
Alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons
Where R2 = CO_TwoWhen NHR6, R6 is a mono- or di-carboxylic acid of an amino acid.
Must not be. M is also Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho, La, Lu, Mo, N
d, Pb, Pd, Pr, Pt, Rh, Sb, Sc, Sm, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb, Zr,
Preferably, it may be Pd, Pt, Ga, Al, Ru, Sn or Zn. Yet another group of compounds has the structure:

[0120]

Embedded image

Here, each of R 1 to R 6 is CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^- (Where X is a charge-balanced ion), C (X)_TwoC (X)_Three(Where X is halogen
), CHO, COCH_Three, CO_TwoH, CO_TwoR7, CONHR7, CH = CHCHO, CH_TwoY (where Y is H,
Halogen, OH, OR7, or a functional group of 100000 Dalton or less), CH = CHCH_TwoO
H, CH = CH- CH_TwoOR7, CH (OH) CH_Three, CH (OR7) CH_Three, H, halogen, alkyl, cyclo
Alkyl (3-6 carbon atoms), aryl, substituted aryl, alkenyl, substituted alk
Nil, alkynyl, substituted alkynyl, amide, ester, NR7R7, CN, OH, OR7,
(CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_n O-alkoxy, (CH_Two)_n SR7, (CH_Two)_nOR7 (where
n = 1, 2, 3, 4, and R7 are functional groups of 100,000 daltons or less), (CH_Two)_nCO_TwoR7 (this
Here, R is H, a physiologically acceptable salt, alkyl (1 to 6 carbon atoms), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl
And n = 1, 2, 3, 4), (CH_Two)_n CONHR7, (CH_Two)_n CON (R7)_Two, CO_TwoR
7, CONHR7, CONR7 R7, SR7 (where R7 is a functional group of 100000 Dalton or less), S
O_ThreeH, SO_ThreeR7, SO_TwoNHR7, SO_TwoN (R7)_Two, SO_TwoN (R7)_Three ⁺X^-(Where R7 is 100000 Dalton
Where X is a charge-balancing ion) and M is In¹¹³, In ¹¹⁵ Or In¹¹³And In¹¹⁵Z is halogen, acetate, OH, alkyl
, Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted
Alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons
. Yet another group of compounds has the structure:

[0122]

Embedded image

Here, R1 is CHCHCH ₂ , CHO, Et, COCH ₃ , R2 is CO ₂ CH ₃ , CO ₂ H, amide, R3 is H, and R4 is CH ₂ CO ₂ CH _{3, CO 2 CH 3, CH} 2 CO 2 H ( or a salt thereof), a CO ₂ H (or a salt thereof), R5 is CH _3, R6 is CO ₂ H, CO ₂ Me, or amides, M is In ^{11 3} , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ , and Z is halogen, acetate or O
H and M is also Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho, In, La
, Lu, Mo, Nd, Pb, Pd, Pr, Pt, Rh, Sb, Sc, Sm, Sn, Tb, Th, Ti, Tl, Tm, U
, V, Y, Yb, Zn or Zr, preferably Pd, Pt, Ga, Al, Ru, Sn or Zn. Yet another group of compounds has the following structural formula:

[0124]

Embedded image

Here, each of R 1 to R 13 is H, halogen, alkyl, vinyl, cycloalkyl (carbon atom
3-6), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl
, Substituted alkynyl, amide, ester, CH = CHCH_TwoN (CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX ^- (Where X is a charge-balanced ion), C (X)_TwoC (X)_Three(Where X is halogen
Atom), NR14R14, CN, OH, OR14, CHO, COCH_Three, (CH_Two)_nOH, (CH_Two)_nSH, (CH _Two )_n O-alkoxy, CH (OH) CH_Three, CH (OR14) CH_Three, (CH_Two)_n SR14, (CH_Two)_n OR14 (here
Wherein n = 1, 2, 3, 4, and R14 are functional groups of 100,000 daltons or less), (CH_Two)_nCO_TwoR
14 (where R14 is H, a physiologically acceptable salt, alkyl (1 to 6 carbon atoms),
Or substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted
Rukinyl and n = 1, 2, 3, 4), (CH_Two)_n CONHR14, (CH_Two)_n CON (R14) _Two , CO_TwoR14, CONHR14, CONR14 R14, SR14 (where R14 is a government of 100,000 daltons or less
Active group), SO_ThreeX, SO_ThreeR14, SO_TwoR14, SO_TwoNHR14, SO_TwoN (R14)_Two, SO_TwoN (R14)_Three ⁺X^-(
Here, R14 is a functional group of 100,000 daltons or less, and X is a charge-balanced ion.
And M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵Where Z is
Halogen, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted
Alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or 1000
It is a functional group of 00 dalton or less. Yet another group of compounds has the structure:

[0126]

Embedded image

Here, each of R1 and R2 is CO 2_TwoR14 (R14 is an alkyl or aryl group), CO _Two H (or its salt), SO_TwoPh or CN, R3, R6, R8 and R12 are Me, R5
Is CH = CH_TwoOr CH (OR14) CH_Three(R14 is an alkyl or aryl group);
, R7, R13, R10 are H and R9, R11 are CH_TwoCH_TwoCO_TwoR15 (where R15 is alkyl or
Or H or a salt of a carboxylic acid), M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵of
A mixture wherein Z is a halogen, acetate or OH, and M is also Ag, Al, Ce, Co
, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho, La, Lu, Mo, Nd, Pb, Pd, Pr, Pt, Rh, Sb
, Sc, Sm, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd, Pt, Ga
, Al, Ru, Sn or Zn. Yet another group of compounds has the following structural formula:

[0128]

Embedded image

Here, each of R 1 to R 7 is CH ₂ CH ₃ , CH = CH ₂ , CH = CHCH ₂ N (CH ₃ ) ₂ , CH = CHCH ₂ N ⁺ (CH ₃ ) ₃ X ⁻ (where, X is a charge-balancing ion), C (X) ₂ C (X) ₃ (where X is a halogen atom), CHO, OR8 or a functional group of up to 100,000 daltons), CH ₂ CO ₂ R
_{8, CH 2 CONHR8, CH =} CHCH 2 OH, CH = CHCH 2 OR8, CH (OH) CH 3, CH (OR8) CH 3, H, halogen, alkyl, cycloalkyl (3-6 carbon atoms), aryl , Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester,
NR8R8, CN, OH, OR8, (CH 2) n OH, (CH 2) n SH, (CH 2) n O- alkoxy, (CH _{2) n} SR8
, (CH _{2) n} OR8 (where, n = 1, 2, 3, 4 and R8 are the following functional groups 100,000 _{daltons), (CH 2) n CO} 2 R8 ( wherein, R8 is H, physiological Salts (alkyl having 1 to 6 carbon atoms), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), CH ₂ ) _n CONHR8, (
_{CH 2) n CON (R8)} 2, CO 2 R8, CONHR8, CONR8R8, SR8 ( where, R8 are the following functional groups 100,000 _{daltons), SO 3 H, SO 3} R8, SO 2 NHR8, SO 2 N _{(R8) 2, SO 2 N} (R8) 3 + X - ( wherein, R8 is the following functional groups 100,000 daltons, and X is a charge balancing ion)
A protein or biomolecule or 100,000 Daltons following functional groups, X is _{O, H 2, (H,} OH), S, (H, OR8), or a ketone protecting group, M is an In ^113, an In ¹¹⁵ Or I
a mixture of n ¹¹³ and In ¹¹⁵ , wherein Z is halogen, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons. M is also Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho, La, Lu, Mo, N
d, Pb, Pd, Pr, Pt, Rh, Sb, Sc, Sm, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or
It may be Zr, preferably Pd, Pt, Ga, Al or Ru. Yet another group of compounds has the structure:

[0130]

Embedded image

Where R 1 is COCH ₃ , R ₃ and R 5 are H, CH ₃ , R 7 is H or OH,
R6 is Me or OH, R4 is H or CO ₂ CH _3, R2 is CO ₂ R8 (wherein, R8 is an alkyl group), M is the In ^113, In ¹¹⁵ or an In ¹¹³ and an In ¹¹⁵ A mixture, Z
Is halogen, acetate or OH, X = O, and M is also Ag, Al, Ce, Co, Cr
, Cu, Dy, Er, Fe, Ga, Hf, Ho, La, Lu, Mo, Nd, Pb, Pd, Pr, Pt, Rh, Sb, Sc
, Sm, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd, Pt, Ga, Al
Or it may be Ru. Yet another group of compounds has the structure:

[0132]

Embedded image

Here, each of R1 to R13 is H, halogen, alkyl, cycloalkyl (3 to 6 carbon atoms).
), Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted
Alkynyl, amide, ester, CH = CHCH_TwoN (CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^- (here
Where X is a charge-balanced ion), C (X)_TwoC (X)_Three(Where X is a halogen atom
), NR14R14, CN, OH, OR14, CHO, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_n O-alkoki
Si, CH (OH) CH_Three, CH (OR14) CH_Three, (CH_Two)_n SR14, (CH_Two)_n OR14 (where n = 1, 2, 3,
4 and R14 are functional groups up to 100000 Dalton), (CH_Two)_nCO_TwoR14 (where R14
Is H, a physiologically acceptable salt, an alkyl (1 to 6 carbon atoms), an aryl,
Alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl
, And n = 1, 2, 3, 4), (CH_Two)_n CONHR14, (CH_Two)_n CON (R14)_Two, CO_TwoR14, CON
HR14, CONR14 R14, SR14 (where R14 is a functional group of 100000 Dalton or less), SO _Three H, SO_ThreeR14, SO_TwoNHR14, SO_TwoN (R14)_Two, SO_TwoN (R14)_Three ⁺X^-(Where R14 is 100000 dal
And X is a charge-balancing ion), and A, B, C
, D is C, N, O⁺, O, Te, P or a combination thereof, where M is In¹¹³, In¹¹⁵Ma
Or In¹¹³And In¹¹⁵Wherein Z is halogen, acetate, OH, alkyl,
Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted al
It is a quinyl, protein or biomolecule or a functional group of 100,000 daltons or less. M
Also include Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho, In, La, Lu, Mo,
Mg, Nd, Pb, Pd, Pr, Pt, Rh, Sb, Sc, Sn, Sm, Tb, Th, Ti, Tl, Tm, U, V, Y
, Yb, Zn, and Zr. Yet another group of compounds has the structure:

[0134]

Embedded image

Here, each of R1 to R13 is H, halogen, alkyl, cycloalkyl (3 to 6 carbon atoms).
), Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted
Alkynyl, amide, ester, CH = CHCH_TwoN (CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^- (here
Where X is a charge-balanced ion), C (X)_TwoC (X)_Three(Where X is a halogen atom
), NR14R14, CN, OH, OR14, CHO, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_n O-alkoki
Si, CH (OH) CH_Three, CH (OR14) CH_Three, (CH_Two)_n SR14, (CH_Two)_n OR14 (where n = 1, 2, 3,
4 and R14 are functional groups up to 100000 Dalton), (CH_Two)_nCO_TwoR14 (where R14
Is H, a physiologically acceptable salt, an alkyl (1 to 6 carbon atoms), an aryl,
Alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl
, And n = 1, 2, 3, 4), (CH_Two)_n CONHR14, (CH_Two)_n CON (R14)_Two, CO_TwoR14, CON
HR14, CONR14 R14, SR14 (where R14 is a functional group of 100000 Dalton or less), SO _Three H, SO_ThreeR14, SO_TwoNHR14, SO_TwoN (R14)_Two, SO_TwoN (R14)_Three ⁺X^-(Where R14 is 100000 dal
And X is a charge-balancing ion), and A, B, C
, D is C, N, O⁺, O, Te, P or a combination thereof, where M is In¹¹³, In¹¹⁵Ma
Or In¹¹³And In¹¹⁵Wherein Z is halogen, acetate, OH, alkyl,
Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted al
It is a quinyl, protein or biomolecule or a functional group of 100,000 daltons or less. M
Can also be Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho, La, Lu, Mo, Mg,
Nd, Pb, Pd, Pr, Pt, Rh, Sb, Sc, Sn, Sm, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb
, Zn or Zr. Yet another group of compounds has the structure:

[0136]

Embedded image

Here, each of R 1 to R 13 is H, halogen, alkyl, cycloalkyl (3 to 6 carbon atoms).
), Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, _{ester, CH = CHCH 2 N (CH} 3) 2, CH = CHCH 2 N + (CH 3) 3 X - ( wherein, X in the charge balancing _{ion), C (X) 2 C} (X) 3 ( wherein, X is halogen atom), NR14R14, CN, OH, OR14, CHO, (CH 2) n OH, (CH 2 _{) n SH, (CH 2)} n O- _{alkoxy, CH (OH) CH 3,} CH (OR14) CH 3, (CH 2) n SR14, (CH 2) n OR14 ( where, n = 1, 2, 3,
4 and R14 is 100,000 daltons or less functional _{groups), (CH 2) n CO} 2 R14 ( wherein, R14
Is H, a physiologically acceptable salt, alkyl (1 to 6 carbon atoms), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4, Yes), (CH ₂ ) _n CONHR14, (CH ₂ ) _n CONH (R14) ₂ , CO ₂ R14, CO
NHR14, CONR14 R14, SR14 (where R14 is a functional group of 100000 Dalton or less), S
_{O 3 H, SO 3 R14,} SO 2 NHR14, SO 2 N (R14) 2, SO 2 N (R14) 3 + X - ( wherein, R14 is 100000 Dalton following functional groups, and X is a charge balancing M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ , and Z is halogen, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl,
Substituted alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons. M is also Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho, In, La, L
u, Mo, Mg, Nd, Pb, Pd, Pr, Pt, Rh, Sb, Sc, Sn, Sm, Tb, Th, Ti, Tl, Tm, U
, V, Y, Yb, Zn or Zr.

Compounds of another family have the following structures:

Embedded image Wherein R1 and R2 are each CO ₂ R14 (where R14 is alkyl or aryl), CO ₂ H (or a salt thereof), SO ₂ Ph, CN or a combination thereof; R3, R6, R8 and R12 are each Me. R5 is, CH = CH _2, or CH (OR14) CH ₃ (wherein R14 is alkyl or aryl), R4, R7, R13, R10 are, H, R9 and R11, respectively, in CH ₂ CH ₂ CO ₂ R15 Where R15 is a salt of alkyl or H or a carboxylic acid. M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ . Z is halide, acetate, or OH. M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf,
Ho, In, La, Lu, Mo, Mg, Nd, Pb, Pd, Pr, Pt, Rh,
Sb, Sc, Sm, Sn, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb,
It can also be Zn or Zr, preferably Pd, Pt, Ga, Al, Ru, Sn or Zn.

Another family of compounds has the structure:

Embedded image In the formula, R1 to R15 are each H, halide, alkyl, vinyl, cyclic alkyl (3 to 6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, CH ＝ CHCH ₂ N (CH ₃ ) ₂ , C
^{_{H = CHCH 2 N + (CH}} 3) 3 X - ( wherein, X is a charge balancing _{ion), C (X) 2 C} (X) 3 ( wherein, X is a halogen), NR16R16, CN, OH, OR16 , CHO, COC
H ₃ , (CH ₂ ) _n OH, (CH ₂ ) _n SH, (CH ₂ ) _n O-alkoxy, SO ₂ Ph, CH
(OH) CH ₃ , CH (OR 14) CH ₃ , (CH ₂ ) _n SR 16, (CH ₂ ) _n OR 16 (where n = 1, 2, 3, 4, and R 16 is a functional group of 100000 dalton or less. is there),(
CH ₂ ) _n CO ₂ R 16 wherein R 16 is H, a physiologically acceptable salt, alkyl (1
-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl or substituted alkynyl, and n = 1, 2, 3, 4), (CH ₂ ) _n CONHR
16, (CH ₂ ) _n CON (R16) ₂ , CO ₂ R16, CONHR16, CONR16
R16, SR16 (wherein, R16 is a functional group of 100,000 daltons or less), SO _{3
X, SO 3 R16, SO 2} NHR16, SO 2 N (R16) 2, SO 2 N (R16) 3 + X - ( wherein, R16 is the following functional groups 100,000 daltons and X is a charge balancing ion M) is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl,
Substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or 10
It is a functional group of 0000 dalton or less. M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf,
Ho, In, La, Lu, Mo, Mg, Nd, Pb, Pd, Pr, Pt, Rh,
Sb, Sc, Sm, Sn, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb,
It can also be Zn or Zr, preferably Pd, Pt, Ga, Al, Ru, Sn or Zn.

Another family of compounds has the structure:

Embedded image Wherein R1, R2, R3 and R4 are each CO ₂ R16 (where R16 is alkyl or aryl), CO ₂ H (or a salt thereof) or SO ₂ Ph, CN; R5, R8, R10 and R14 is Me. R7 is, CH = CH ₂ or CH (OR16) CH ₃ (wherein R16 is alkyl or aryl) is. R6, R9, R12 and R15 are each H. R11 and R13 are each CH ₂ CH ₂ CO ₂ R16 (wherein R16 is alkyl or H or a salt of a carboxylic acid), or an amide. M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ . Z is halide, acetate, or OH. M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf,
Ho, La, Lu, Mo, Mg, Nd, Pb, Pd, Pr, Pt, Rh, Sb,
It can also be Sc, Sm, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd, Pt, Ga, Al, Ru, Sn or Zn.

Another family of compounds has the structure:

Embedded imageIn the formula, R1 to R13 are each H, halide, alkyl, cyclic alkyl (3 to
6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl
, Substituted alkynyl, amide, ester, CH = CHCH_TwoN (CH_Three)_Two, CH = C
HCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X)_TwoC (X)_Three(Where X
Is halogen), NR14R14, CN, OH, OR14, CHO, (CH_Two)_nOH
, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, CH (OH) CH_Three, CH (OR14)
CH_Three, (CH_Two)_nSR14, (CH_Two)_nOR14 (where n = 1, 2, 3, 4, and
R14 is a functional group having a molecular weight of 100,000 daltons or less), (CH_Two)_nCO_TwoR14 (wherein, R
14 is H, a physiologically acceptable salt, alkyl (1 to 6 carbons), aryl, substituted
Reel, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl
, And n = 1, 2, 3, 4), (CH_Two)_nCONHR14, (CH_Two)_nCON (R14
)_Two, CO_TwoR14, CONHR14, CONR14R14, SR14 (wherein, R1
4 is a functional group of 100,000 daltons or less), SO_ThreeH, SO_ThreeR14, SO_TwoNHR
14, SO_TwoN (R14)_Two, SO_TwoN (R14)_Three ⁺X^-(Where R14 is 100,000 daltons
A, B, C, D are:
C, N, O⁺, O, S, Te, P or a combination thereof; M is In¹¹³, In ¹¹⁵ Or In¹¹³And In¹¹⁵Z is halide, acetate, OH,
Alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl
, A substituted alkynyl, protein or biomolecule with a functional group of 100,000 daltons or less
. M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf,
Ho, In, La, Lu, Mo, Mg, Nd, Pb, Pd, Pr, Pt, Rh,
Sb, Sc, Sm, Sn, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb,
It can also be Zn or Zr, preferably Pd, Pt, Ga, Al, Ru, Sn or Zn.
Can be.

Another family of compounds has the structure:

Embedded imageIn the formula, R1 to R14 are each H, halide, alkyl, cyclic alkyl (3 to
6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl
, Substituted alkynyl, amide, ester, CH = CHCH_TwoN (CH_Three)_Two, CH = C
HCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X)_TwoC (X)_Three(Where X
Is halogen), NR15R15, CN, OH, OR15, CHO, (CH_Two)_nOH
, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, CH (OH) CH_Three, CH (OR15)
CH_Three, (CH_Two)_nSR15, (CH_Two)_nOR15 (where n = 1, 2, 3, 4, and
R15 is a functional group having a molecular weight of 100,000 daltons or less), (CH_Two)_nCO_TwoR15 (wherein, R
15 is H, a physiologically acceptable salt, alkyl (1 to 6 carbons), aryl, substituted
Reel, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl
, And n = 1, 2, 3, 4), (CH_Two)_nCONHR15, (CH_Two)_nCON (R15
)_Two, CO_TwoR15, CONHR15, CONR15R15, SR15 (wherein, R1
5 is a functional group of 100,000 daltons or less), SO_ThreeH, SO_ThreeR15, SO_TwoNHR
15, SO_TwoN (R15)_Two, SO_TwoN (R15)_Three ⁺X^-(Where R15 is 100,000 dart
A, B, C, D are:
C, N, O⁺, O, S, Te, P or a combination thereof; M is In¹¹³, In ¹¹⁵ Or In¹¹³And In¹¹⁵Z is halide, acetate, OH,
Alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl
With a substituted alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons
is there. M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf,
Ho, La, Lu, Mo, Mg, Nd, Pb, Pd, Pr, Pt, Rh, Sb,
Sc, Sm, Sn, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb, Zn or
May also be Zr.

Another family of compounds has the structure:

Embedded imageIn the formula, R1 to R4 are each CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR5, C
ONHR5, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
5 or 100000 Dalton or less), CH_TwoCO_TwoR5, CH_TwoCONHR
5, CH = CHCH_TwoOH, CH = CHCH_TwoOR5, CH (OH) CH_Three, CH (O
R5) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR5R5, CN, OH, OR5, CHO, (CH_Two)_nOH, (
CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR5, (CH_Two)_nOR5 (where
, N = 1, 2, 3, 4, and R5 is a functional group of 100,000 daltons or less), (CH _Two )_nCO_TwoR5 (wherein R5 is H, a physiologically acceptable salt, alkyl (1-6 carbon atoms)
), Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or
Substituted alkynyl and n = 1, 2, 3, 4), (CH_Two)_nCONHR5, (C
H_Two)_nCON (R5)_Two, CO_TwoR5, CONHR5, CONR5R5, SR5 (R5
Is a functional group of 100000 Dalton or less), SO_ThreeH, SO_ThreeR5, SO_TwoNHR5,
SO_TwoN (R5)_Two, SO_TwoN (R5)_Three ⁺X^-(Where R5 is a sensory of 100,000 daltons or less
And X is a charge balance ion), a protein or biomolecule or 10,000
A and B are O, NH, NR5 or a combination thereof.
X is O, NR5, wherein R5 is H, alkyl (1-10 carbons),
Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted al
(Quinyl, amino acid, amino acid ester or a functional group of 100,000 daltons or less)
M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵Z is a halide,
Acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted al
Kenyl, alkynyl, substituted alkynyl, protein or biomolecule or 100,000 dal
Functional group. M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf,
Ho, La, Lu, Mo, Mg, Nd, Pb, Pd, Pr, Pt, Rh, Sb,
Sc, Sm, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferred
Alternatively, it may be Pd, Pt, Ga, Al, Ru, Sn or Zn.

Another family of compounds has the structure:

Embedded imageIn the formula, R1 to R8 are each CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR9, C
ONHR9, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
9 or 100000 Dalton or less), CH_TwoCO_TwoR9, CH_TwoCONHR
9, CH = CHCH_TwoOH, CH = CHCH_TwoOR9, CH (OH) CH_Three, CH (O
R9) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR9R9, CN, OH, OR9, CHO, (CH_Two)_nOH, (
CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR9, (CH_Two)_nOR9 (in the formula
, N = 1, 2, 3, 4, and R9 is a functional group of 100,000 daltons or less), (CH _Two )_nCO_TwoR9 (wherein R9 is H, a physiologically acceptable salt, alkyl (1-6 carbon atoms)
), Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or
Substituted alkynyl and n = 1, 2, 3, 4), (CH_Two)_nCONHR9, (C
H_Two)_nCON (R9)_Two, CO_TwoR9, CONHR9, CONR9R9, SR9 (R9
Is a functional group of 100000 Dalton or less), SO_ThreeH, SO_ThreeR9, SO_TwoNHR9,
SO_TwoN (R9)_Two, SO_TwoN (R9)_Three ⁺X^-(Wherein R9 is a sensory of 100,000 daltons or less
And X is a charge balance ion), a protein or biomolecule or 10,000
X is O, H_Two, (H, OH), (H, OR9), S,
Is a ketone protecting group; M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵In a mixture of
Yes; Z is halide, acetate, OH, alkyl, aryl, substituted aryl,
Alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or raw
It is a body molecule or a functional group of 100,000 daltons or less. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Hf, Ho, La,
Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn, Tb,
Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd, Pt,
It may be Ga, Al, Ru, Sn or Zn.

Compounds of another family have the following structures:

Embedded imageIn the formula, R1 to R6 each represent CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR7, C
ONHR7, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
7 or 100000 Dalton or less), CH_TwoCO_TwoR7, CH_TwoCONHR
7, CH = CHCH_TwoOH, CH = CHCH_TwoOR7, CH (OH) CH_Three, CH (O
R7) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR7R7, CN, OH, OR7, CHO, (CH_Two)_nOH, (
CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR7, (CH_Two)_nOR7 (where
, N = 1, 2, 3, 4, and R7 is a functional group of 100,000 daltons or less), (CH _Two )_nCO_TwoR7 (wherein R7 is H, a physiologically acceptable salt, alkyl (1-6 carbon atoms)
), Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or
Substituted alkynyl and n = 1, 2, 3, 4), (CH_Two)_nCONHR7, (C
H_Two)_nCON (R7)_Two, CO_TwoR7, CONHR7, CONR7R7, SR7 (R7
Is a functional group of 100000 Dalton or less), SO_ThreeH, SO_ThreeR7, SO_TwoNHR7,
SO_TwoN (R7)_Two, SO_TwoN (R7)_Three ⁺X^-(Where R7 is a sensory of 100,000 daltons or less
And X is a charge balance ion), a protein or biomolecule or 10,000
X is O, NR7, wherein R7 is H, alkyl
(1-10 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl,
Lucinyl, substituted alkynyl, amino acid, amino acid ester or 100,000 dalton or less
A and B are O, NH, NR7 or a combination thereof;
M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵Z is a halide, a
Acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alk
Nil, alkynyl, substituted alkynyl, protein or biomolecule or 100,000 daltons
The following functional groups. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Hf, Ho, La,
Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn, Tb,
Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd, Pt,
It may be Ga, Al, Ru, Sn or Zn.

Another family of compounds has the following structures:

Embedded image Wherein; R1 is _{CH = CH 2, Et, CHO} , or COCH ₃ R2 is _{CO 2 CH 3, CO 2 H} , CO 2 R7 ( wherein, R7 is alkyl, phenyl), or amide R3 is H R4 is Me R5 and R6 are each OH A and B are each O or NR7 (R7 is alkyl). X is (R7, alkyl, amino, alcohol-containing group, or an ether containing group) O or NR7 mixtures Z of M is an In ^113, an In ¹¹⁵ or an In ¹¹³ and an In ¹¹⁵ is a halide, acetate, or OH. M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf,
Ho, La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm,
Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd;
It may be Pt, Ga, Al, Ru, Sn or Zn.

Compounds of another family have the following structures:

Embedded imageIn the formula, R1 to R6 each represent CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR7, C
ONHR7, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
7 or 100000 Dalton or less), CH_TwoCO_TwoR7, CH_TwoCONHR
7, CH = CHCH_TwoOH, CH = CHCH_TwoOR7, CH (OH) CH_Three, CH (O
R7) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR7R7, CN, O, S, NHR7, OH, OR7, CHO
, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR7, (
CH_Two)_nOR7 (where n = 1, 2, 3, 4, and R7 is a government of 100,000 daltons or less)
Active group), (CH_Two)_nCO_TwoR7 (wherein R7 is H, a physiologically acceptable salt,
Alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl
, Alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH_Two) _n CONHR7, CO_TwoR7, CONHR7, CONR10R7, SR7 (wherein,
R7 is a functional group of 100000 Dalton or less), SO_ThreeH, SO_ThreeR7, SO_TwoNHR
7, SO_TwoN (R7)_Two, SO_TwoN (R7)_Three ⁺X^-(Where R7 is less than 100,000 daltons
X is a charge-balancing ion), a protein or biomolecule or 1
X is O, H_Two, (H, OH), (H, OR8) S
Or a ketone protecting group; M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵Mixing
Z is halide, acetate, OH, alkyl, aryl, substituted aryl
Alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or
Is a biomolecule or a functional group of 100,000 daltons or less. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn,
Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd;
It may be Pt, Ga, Al, Ru, Sn or Zn.

Compounds of another family have the following structures:

Embedded image Wherein R1 is CH ＝ CH ₂ , Et, CHO, or COCH ₃ R2 is CO ₂ CH ₃ , CO ₂ H, CO ₂ R7 (where R7 is an alkyl or phenyl group)
Or amide R3 is H R4 is H or CO ₂ CH ₃ R5 is O or NR7 (where R7 is alkyl) R6 is Me X is OM is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ or In ¹¹³ and In ¹¹⁵ Z is Halide, acetate or OH. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn,
Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd;
It may be Pt, Ga, Al, Ru, Sn or Zn.

Compounds of another family have the following structures:

Embedded imageIn the formula, R1 to R8 are each CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR9, C
ONHR9, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
9 or 100000 Dalton or less), CH_TwoCO_TwoR9, CH_TwoCONHR
9, CH = CHCH_TwoOH, CH = CHCH_TwoOR9, CH (OH) CH_Three, CH (O
R9) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR9R9, CN, O, S, NHR9, OH, OR9, CHO
, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR9, (
CH_Two)_nOR9 (where n = 1, 2, 3, 4, and R9 is a government of 100,000 daltons or less)
Active group), (CH_Two)_nCO_TwoR9 (wherein R9 is H, a physiologically acceptable salt,
Alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl
, Alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH_Two) _n CONHR9, (CH_Two)_nCON (R9)_Two, CO_TwoR9, CONHR9, CONR
10R9, SR9 (R9 is a functional group of 100000 Dalton or less), SO_ThreeH, SO_Three R9, SO_TwoNHR9, SO_TwoN (R9)_Two, SO_TwoN (R9)_Three ⁺X^-(Where R9 is 1000
A functional group of less than or equal to 00 Dalton, and X is a charge-balancing ion), protein
Or a biomolecule or a functional group of 100,000 daltons or less;¹¹³, In¹¹⁵or
Is In¹¹³And In¹¹⁵Z is halide, acetate, OH, alkyl
, Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted
Alkynyl, protein or biomolecule or a functional group of 100,000 daltons or less.
M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn,
Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd;
It may be Pt, Ga, Al, Ru, Sn or Zn.

Yet another family of compounds has the structure:

Embedded image Wherein R1 is CH ＝ CH ₂ , Et, CHO, or COCH ₃ R5 is O or NR7 (where R7 is alkyl) R7 is Me R3 is H R4 and R8 is H, CO ₂ CH ₃ , CH ₂ H (Or a salt thereof), CO ₂ R7 (R7 is an alkyl or phenyl group), an amide, CH ₂ CO ₂ CH ₃ , CH ₂ CO ₂ H (or a salt thereof),
CO ₂ R 9 (R 9 is an alkyl or phenyl group) or amide R 2 is CO ₂ CH ₃ , CH ₂ H, CO ₂ R 9 (R 9 is an alkyl or phenyl group), or amide M is In ¹¹³ , In ¹¹⁵ or In ¹¹³ The mixture Z of In ¹¹⁵ is halide, acetate, or OH. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn,
Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd;
It may be Pt, Ga, Al, Ru, Sn or Zn.

Another family of compounds has the structure:

Embedded imageIn the formula, R1 to R5 are each CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR6, C
ONHR6, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
6 or 100000 Dalton or less), CH_TwoCO_TwoR6, CH_TwoCONHR
6, CH = CHCH_TwoOH, CH = CHCH_TwoOR8, CH (OH) CH_Three, CH (O
R6) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR6R6, CN, O, S, NHR6, OH, OR6, CHO
, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR6, (
CH_Two)_nOR6 (where n = 1, 2, 3, 4, and R6 is a government of 100,000 daltons or less)
Active group), (CH_Two)_nCO_TwoR6 wherein R6 is H, a physiologically acceptable salt,
Alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl
, Alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH_Two) _n CONR6, CO_TwoR6, CONHR6, CONR6R6, SR6 (wherein, R6
Is a functional group of 100000 Dalton or less), SO_ThreeH, SO_ThreeR6, SO_TwoNHR6,
SO_TwoN (R6)_Two, SO_TwoN (R6)_Three ⁺X^-(Wherein, R6 is a sensory of 100,000 daltons or less
And X is a charge balance ion), a protein or biomolecule or 10,000
X is O, NR6 (where R6 is H, alkyl (1
-10 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alk
Nyl, substituted alkynyl, amino acid, amino acid ester or 100,000 daltons or less
A and B are O, NH, NR6 or a combination thereof; Z is
Halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl
A substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or
It is a functional group of 100000 daltons or less. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn,
Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd;
It may be Pt, Ga, Al, Ru, Sn or Zn.

Another family of compounds has the structure:

Embedded image Wherein; A and B are each O or NR6 (wherein, R6 is an alkyl or phenyl group) R1 is _{CH = CH 2, Et, CHO} , or COCH ₃ R4 is O or NR6 (wherein, R6 is alkyl) R5 is Me R3 is H R2 is _{CO 2 CH 3, CH 2 H} , CO 2 R6 (R6 is an alkyl or phenyl group), or an amide X is O, NR6 (R6 is alkyl, amino, alcohol-containing group, or an ether containing Group) M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ Z is halide, acetate, OH. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn,
Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd;
It may be Pt, Ga, Al, Ru, Sn or Zn.

Another family of compounds has the structure:

Embedded imageIn the formula, R1 to R6 each represent CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR7, C
ONHR7, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
7 or 100000 Dalton or less), CH_TwoCO_TwoR7, CH_TwoCONHR
7, CH = CHCH_TwoOH, CH = CHCH_TwoOR7, CH (OH) CH_Three, CH (O
R7) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR7R7, CN, O, S, NHR7, OH, OR7, CHO
, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR7, (
CH_Two)_nOR7 (where n = 1, 2, 3, 4, and R7 is a government of 100,000 daltons or less)
Active group), (CH_Two)_nCO_TwoR7 (wherein R7 is H, a physiologically acceptable salt,
Alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl
, Alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH_Two) _n CONR7, CO_TwoR7, CONHR7, CONR7R7, SR7 (R7 is 10,000
0 Dalton or less), SO_ThreeH, SO_ThreeR7, SO_TwoNHR7, SO_TwoN
(R7)_Two, SO_TwoN (R7)_Three ⁺X^-(Wherein R7 is a functional group of 100,000 daltons or less
, And X is a charge-balancing ion), protein or biomolecule or 100,000 daltons
X is O, H_Two, (H, OH), (H, OR7), S, or
M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵Is a mixture of
Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alk;
Kenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or organism
Or a functional group of 100,000 daltons or less. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn,
Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd;
It may be Pt, Ga, Al, Ru, Sn or Zn.

Another family of compounds has the structure:

Embedded image Wherein R1 is CH ＝ CH ₂ , Et, CHO, or COCH ₃ R6 is O or NR7 (where R7 is an alkyl group) R5 is Me R3 is H R4 is H or CO ₂ CH ₃ R2 is CO ₂ CH ₃ , CH ₂ H, CO ₂ R 7 (R 7 is alkyl, phenyl), or amide X is OM for In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ Z is halide, acetate, or OH. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn,
Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd;
It may be Pt, Ga, Al, Ru, Sn or Zn.

Another family of compounds has the structure:

Embedded imageIn the formula, R1 to R7 are each CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR8, C
ONHR8, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
8 or 100000 Dalton or less), CH_TwoCO_TwoR8, CH_TwoCONHR
8, CH = CHCH_TwoOH, CH = CHCH_TwoOR8, CH (OH) CH_Three, CH (O
R8) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR8R8, CN, O, S, NHR8, OH, OR8, CHO
, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR8, (
CH_Two)_nOR8 (where n = 1, 2, 3, 4, and R8 is a government of 100,000 daltons or less)
Active group), (CH_Two)_nCO_TwoR8 (where R8 is H, a physiologically acceptable salt,
Alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl
, Alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH_Two) _n CONR8, CO_TwoR8, CONHR8, CONR8R8, SR8 (wherein, R8
Is a functional group of 100000 Dalton or less), SO_ThreeH, SO_ThreeR8, SO_TwoNHR8,
SO_TwoN (R8)_Two, SO_TwoN (R8)_Three ⁺X^-(Where R8 is a sensory of 100,000 daltons or less
And X is a charge balance ion), a protein or biomolecule or 10,000
0 Dalton or less functional group; M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵of
A mixture; Z is halide, acetate, OH, alkyl, aryl, substituted
Reel, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein
Quality or biomolecules or functional groups of 100,000 daltons or less.

Compounds of another family have the following structures:

Embedded image Wherein R1 is CH ＝ CH ₂ , Et, CHO, or COCH ₃ R6 is O, or NR8 (where R8 is alkyl) R5 is Me R3 is H R4 and R7 is H, CO ₂ CH ₃ , CH ₂ H (or a salt thereof), CO ₂ R8 (R8 is alkyl or phenyl), amide, CH ₂ CO ₂ CH ₃ , CH ₂ CO ₂ H (or a salt thereof), C
O ₂ R 8 (R 8 is an alkyl or phenyl group) R 2 is CO ₂ CH ₃ , CH ₂ H, CO ₂ R 8 (R 8 is alkyl or phenyl), or amide M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ Z is halide, acetate, OH. M is Pd Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf,
Ho, La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm,
It can also be Sn, Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd, Pt, Ga, Al, Ru, Sn or Zn.

Compounds of another family have the following structures:

Embedded image Wherein R1 is CH ＝ CH ₂ , Et, CHO or COCH ₃ R4 is Me R3 is H R2 is CO ₂ CH ₃ , CO ₂ H, CO ₂ R5 (R5 is alkyl or phenyl), or amides A and B are , mixture M of (the R5 alkyl) O or NR5 each X is O, NR5 (R5 is alkyl, amino, alcohol-containing group, or an ether containing group) M is a an in ^113, an in ¹¹⁵ or an in ¹¹³ an in ¹¹⁵ is, Ag , Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf,
Ho, La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm,
Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd;
It may be Pt, Ga, Al, Ru, Sn or Zn.

Another family of compounds has the structure:

Embedded image In the formula: R1 is CH ＝ CH ₂ , Et, CHO or COCH ₃ R5 is Me R4 is CO ₂ CH ₃ , CO ₂ H, CO ₂ R9 (R9 is an alkyl or phenyl group), amide, CH ₂ CO ₂ CH ₃ , CH ₂ CO ₂ H, or CH ₂ CO ₂ R9 (R9 is an alkyl or phenyl group) R3 is H R2 and R8 are CO ₂ CH ₃ , CH ₂ H, CO ₂ R9 (R9 is an alkyl or phenyl group) Or amide M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ Z is halide, acetate or OH. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Hf, Ho, La,
Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn, Tb,
Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd, Pt,
It may be Ga, Al, Ru, Sn or Zn.

Yet another family of compounds has the structure:

Embedded imageIn the formula, R1 to R5 are each CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR6, C
ONHR6, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
6 or 100000 Dalton or less), CH_TwoCO_TwoR6, CH_TwoCONHR
6, CH = CHCH_TwoOH, CH = CHCH_TwoOR6, CH (OH) CH_Three, CH (O
R6) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR6R6, CN, O, S, NHR6, OH, OR6, CHO
, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR6, (
CH_Two)_nOR6 (where n = 1, 2, 3, 4, and R6 is a government of 100,000 daltons or less)
Active group), (CH_Two)_nCO_TwoR6 wherein R6 is H, a physiologically acceptable salt,
Alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl
, Alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH_Two) _n CONR6, CO_TwoR6, CONHR6, CONR6R6, SR6 (wherein, R6
Is a functional group of 100000 Dalton or less), SO_ThreeH, SO_ThreeR6, SO_TwoNHR6,
SO_TwoN (R6)_Two, SO_TwoN (R6)_Three ⁺X^-(Wherein, R6 is a sensory of 100,000 daltons or less
And X is a charge balance ion), a protein or biomolecule or 10,000
A and B are O, NH, NR6 or a combination thereof.
X is O, NR6 (where R6 is H, alkyl (1-10 carbons), aryl)
, Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl
, An amino acid, an amino acid ester or a functional group of up to 100,000 daltons);
In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵Z is halide, acete
, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl
, Alkynyl, substituted alkynyl, protein or biomolecule or 100,000 daltons or less
The functional group below. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn,
Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd;
It may be Pt, Ga, Al, Ru, Sn or Zn.

Another family of compounds has the structure:

Embedded image In the formula: R1 is CH ＝ CH ₂ , Et, CHO or COCH ₃ R5 is O or NR6 (R6 is alkyl) R4 is Me R3 is HR R2 is CO ₂ CH ₃ , CH ₂ H, CO ₂ R5 (R5 is alkyl or phenyl), or amide A and B, O, NR6 (R6 is an alkyl or phenyl radical) X is O, NR6 (R6 is alkyl), amino, alcohol-containing group, or an ether containing group M is an in ^113, an in ¹¹⁵ Or a mixture of In ¹¹³ and In ¹¹⁵ Z is halide, acetate, or OH. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr or Rh, preferably Ga, Al,
It can also be Ru, Sn or Zn.

Yet another family of compounds has the structure:

Embedded imageIn the formula, R1 to R24 are each CH_TwoCH_Three, CH = CHCH_TwoN (CH_Three)_Two, C
H = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), CH = CH_Two, C (
X)_TwoC (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR25
, CONHR25, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH
, OR25 or a functional group of 100000 Dalton or less), CH_TwoCO_TwoR25, CH_Two CONHR25, CH = CHCH_TwoOH, CH = CHCH_TwoOR25, CH (OH)
CH_Three, CH (OR25) CH_Three, H, halide, alkyl, cyclic alkyl (3-6
Carbon), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl,
Substituted alkynyl, amide, ester, NR25R25, CN, O, S, NHR2
5, OH, OR25, CHO, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-Al
Koxy, (CH_Two)_nSR25, (CH_Two)_nOR25 (where n = 1, 2, 3, 4,
R25 is a functional group of 100,000 daltons or less), (CH_Two)_nCO_TwoR25 (wherein
R25 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted
Aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl
And n = 1, 2, 3, 4), (CH_Two)_nCON (R25)_Two, (CH_Two)_nCONHR
25, CO_TwoR25, CONHR25, CONR25R25, SR25 (where R
25 is a functional group of 100,000 daltons or less), SO_ThreeH, SO_ThreeR25, SO_TwoNH
R25, SO_TwoN (R25)_Two, SO_TwoN (R25)_Three ⁺X^-(Where R25 is 100000 dal
Or less, and X is a charge-balancing ion), protein or
A, B, C, D is: C, N, O ⁺ , O, S, Te, P, N⁺(R25) X^-(Where R25 is a government of 100,000 daltons or less
And X is a charge-balancing ion), or a combination thereof;
Is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵Z is a halide, acetyl
Tate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl
Alkynyl, substituted alkynyl, protein or biomolecule or 100,000 daltons
These are the following functional groups. M can also be Pd or Ga.

Yet another family of compounds has the structure:

Embedded imageIn the formula, R1 to R8 are each CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR9, C
ONHR9, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
9 or 100000 Dalton or less), CH_TwoCO_TwoR9, CH_TwoCONHR
9, CH = CHCH_TwoOH, CH = CHCH_TwoOR9, CH (OH) CH_Three, CH (O
R9) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR9R9, CN, O, S, NHR9, OH, OR9, CHO
, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR9, (
CH_Two)_nOR9 (where n = 1, 2, 3, 4, and R9 is a government of 100,000 daltons or less)
Active group), (CH_Two)_nCO_TwoR9 (wherein R9 is H, a physiologically acceptable salt,
Alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl
, Alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH_Two) _n CONHR9, (CH_Two)_nCON (R9)_Two, CO_TwoR9, CONHR9, CONR
9R9, SR9 (R9 is a functional group of 100000 dalton or less), SO_ThreeH, SO_ThreeR
9, SO_TwoNHR9, SO_TwoN (R9)_Two, SO_TwoN (R9)_Three ⁺X^-(Where R9 is 100000
Sub-Dalton functional group and X is a charge balance ion), protein or
Is a biomolecule or a functional group of 100,000 daltons or less. A, B, C, D: C, N, O⁺, O, S, Te, P, N⁺(R9) X^-(Wherein, R9
Is a functional group of 100000 Daltons or less, and X is a charge balance ion), or
M is In;¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵In a mixture of
Yes; Z is halide, acetate, OH, alkyl, aryl, substituted aryl,
Alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or raw
X is O, NR9 (where R9 is
H, alkyl (1-10 carbons), aryl, substituted aryl, alkenyl, substituted al
Kenyl, alkynyl, substituted alkynyl, amino acid, amino acid ester or 100000
It is a functional group of Dalton or less. M can also be Pd or Ga.

Yet another family of compounds has the structure:

Embedded image Wherein, R1～R22 each _{CH 2 CH 3, CH = CH} 2, CH = CHCH 2 N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is a halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R23,
CONHR23, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR23 or 100,000 Daltons following functional _{groups), CH 2 CO 2 R23,} CH 2 C
_{ONHR23, CH = CHCH 2 OH,} CH = CHCH 2 OR23, CH (OH) C
_{H 3, CH (OR23) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR23R23, CN, O, S, NHR23
, OH, OR23, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR23,} (CH 2) n OR23 ( wherein, n = 1 , 2, 3, 4, and R23 are functional groups of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R23 (wherein R
23 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); (CH ₂ ) _n CONHR23, (CH ₂ ) _n CON (R23
) ₂ , CO ₂ R23, CONHR23, CONR23R23, SR23 (wherein R2
3 is a functional group of 100000 Dalton or less), SO ₃ H, SO ₃ R23, SO ₂ NHR
23, SO ₂ N (R23) ₂ , SO ₂ N (R23) ₃ ⁺ X ⁻ (where R23 is a functional group of 100,000 daltons or less and X is a charge balancing ion), protein or biomolecule or A, B, C, D, E and F are C
, N, O ⁺ , O, S, Te, P, N ⁺ (R23) X ⁻ , wherein R23 is a functional group of up to 100,000 daltons and X is a charge balancing ion, or a combination thereof. M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule Or 100000
It is a functional group of Dalton or less. M can also be Pd or Ga.

Another family of compounds has the following structures:

Embedded image In the formula, R1 to R18 are each CH ₂ CH ₃ , CH 2CH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R19,
CONHR19, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR 19 or a functional group having a molecular weight of 100,000 daltons or less), CH ₂ CO ₂ R 19, CH ₂ C
_{ONHR19, CH = CHCH 2 OH,} CH = CHCH 2 OR19, CH (OH) C
_{H 3, CH (OR19) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR19R19, CN, O, S, NHR19
, OH, OR19, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- alkoxy, (CH _{2) n} SR19, or (CH _{2) n} OR19 (wherein, n = 1, 2, 3, 4,
And R19 is 100,000 daltons or less functional groups), (CH _{2) n} CO ₂ R19 (wherein, R19 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, Alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH ₂ ) _n CONHR 19, (CH ₂ ) _n CON (R
19) ₂ , CO ₂ R19, CONHR19, CONR19R19, SR19 (R19
Is a functional group of 100000 Dalton or less), SO ₃ H, SO ₃ R19, SO ₂ NHR1
9, SO ₂ N (R19) ₂ , SO ₂ N (R19) ₃ ⁺ X ⁻ (where R19 is a functional group of 100,000 daltons or less and X is a charge balancing ion), a protein or a biomolecule or A, B, C, D, E, F are CH,
N, O ⁺ , O, S, Te, P, N ⁺ (R19) X ⁻ (where R19 is a functional group of 100,000 daltons or less and X is a charge balance ion), or a combination thereof. Yes; M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or It is a functional group of 100000 daltons or less. M can also be Pd or Ga.

Another family of compounds has the structure:

Embedded image In the formula, R1 to R20 are each CH ₂ CH ₃ , CH 2CH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (wherein X is halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R21,
CONHR21, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR21 or a functional group having a molecular weight of 100,000 daltons or less), CH ₂ CO ₂ R 21, CH ₂ C
_{ONHR21, CH = CHCH 2 OH,} CH = CHCH 2 OR21, CH (OH) C
_{H 3, CH (OR21) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR21R21, CN, O, S, NHR21
, OH, OR21, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR21,} (CH 2) n OR21 ( wherein, n = 1 , 2, 3, 4, and R21 are functional groups of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R21
21 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); (CH ₂ ) _n CONHR21, (CH ₂ ) _n CON (R21
) ₂ , CO ₂ R21, CONHR21, CONR21R21, SR21 (wherein R2
1 is a functional group of 100000 Dalton or less), SO ₃ H, SO ₃ R21, SO ₂ NHR
21, SO ₂ N (R21) ₂ , SO ₂ N (R21) ₃ ⁺ X ⁻ (wherein R21 is a functional group of 100,000 daltons or less and X is a charge balancing ion), protein or biomolecule or A, B, C, D, E, F are C,
N, O ⁺ , O, S, Te, P, N ⁺ (R21) X ⁻ (where R21 is a functional group of 100000 daltons or less and X is a charge balance ion), or a combination thereof. Yes; M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or It is a functional group of 100000 daltons or less. M can also be Pd or Ga.

Yet another family of compounds has the structure:

Embedded image In the formula, R1 to R24 are each CH ₂ CH ₃ , CH 2CH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is a halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R25,
CONHR25, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR25 or 100,000 Daltons following functional _{groups), CH 2 CO 2 R25,} CH 2 C
_{ONHR25, CH = CHCH 2 OH,} CH = CHCH 2 OR25, CH (OH) C
_{H 3, CH (OR25) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR25R25, CN, O, S, NHR25
, OH, OR25, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR25,} (CH 2) n OR25 ( wherein, n = 1 , 2, 3, 4, and R25 are functional groups of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R25 (wherein, R
25 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); (CH ₂ ) _n CONHR25, (CH ₂ ) _n CON (R25
) ₂ , CO ₂ R25, CONHR25, CONR25R25, SR25 (wherein R2
5 is a functional group of 100,000 dalton or less), SO ₃ H, SO ₃ R25, SO ₂ NHR
25, SO ₂ N (R25) ₂ , SO ₂ N (R25) ₃ ⁺ X ⁻ (where R25 is a functional group of 100,000 daltons or less and X is a charge balancing ion), protein or biomolecule or A, B, C, D, E, F are C,
N, O ⁺ , O, S, Te, P, N ⁺ (R25) X ⁻ (where R25 is a functional group of 100,000 daltons or less and X is a charge balancing ion), or a combination thereof. Yes; M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or It is a functional group of 100000 daltons or less. M can also be Pd or Ga.

Yet another family of compounds has the structure:

Embedded image Wherein, R1～R32 each _{CH 2 CH 3, CH = CH} 2, CH = CHCH 2 N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is a halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R33,
CONHR33, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR 33 or a functional group having a molecular weight of 100,000 daltons or less), CH ₂ CO ₂ R 33, CH ₂ C
_{ONHR33, CH = CHCH 2 OH,} CH = CHCH 2 OR33, CH (OH) C
_{H 3, CH (OR33) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR33R33, CN, O, S, NHR33
, OH, OR33, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR33,} (CH 2) n OR33 ( wherein, n = 1 , 2, 3, 4, and R33 are functional groups of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R33 (where R
33 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); (CH ₂ ) _n CONHR33, (CH ₂ ) _n CON (R33
) ₂ , CO ₂ R33, CONHR33, CONR33R33, SR33 (wherein R3
3 is a functional group of 100,000 daltons or less), SO ₃ H, SO ₃ R33, SO ₂ NHR
33, SO ₂ N (R33) ₂ , SO ₂ N (R33) ₃ ⁺ X ⁻ (wherein R33 is a functional group of 100,000 daltons or less and X is a charge balancing ion), protein or biomolecule or A, B, C are C, N, O ⁺ , O
, S, Te, P, N ⁺ (R33) X ⁻ , wherein R33 is a functional group of up to 100,000 daltons and X is a charge-balancing ion, or a combination thereof;
n ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl,
Alkynyl, substituted alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons. M can also be Pd or Ga.

Yet another family of compounds has the structure:

Embedded image In the formula, R1 to R18 are each CH ₂ CH ₃ , CH 2CH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R19,
CONHR19, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR 19 or a functional group having a molecular weight of 100,000 daltons or less), CH ₂ CO ₂ R 19, CH ₂ C
_{ONHR19, CH = CHCH 2 OH,} CH = CHCH 2 OR19, CH (OH) C
_{H 3, CH (OR19) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR19R19, CN, O, S, NHR19
, OH, OR19, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR19,} (CH 2) n OR19 ( wherein, n = 1 , 2,3,4, and R19 are the following functional groups 100,000 _{daltons), (CH 2) n CO} 2 R19 ( wherein, R
19 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); _{(CH 2) n CONHR19, (} CH 2) n CON (R19
) ₂ , CO ₂ R19, CONHR19, CONR10R19, SR19 (wherein R1
9 is a functional group of 100,000 daltons or less), SO ₃ H, SO ₃ R19, SO ₂ NHR
19. SO ₂ N (R19) ₂ , SO ₂ N (R19) ₃ ⁺ X ⁻ (where R19 is a functional group of 100,000 daltons or less and X is a charge balancing ion), protein or biomolecule or It is a functional group of 100000 daltons or less. U, V, X, Y are C, N, O ⁺
, O, S, Te, P, N ⁺ (R19) X ⁻ , where R19 is a functional group of up to 100,000 daltons and X is a charge balancing ion, or a combination thereof;
Is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or up to 100,000 daltons Is a functional group. M can also be Pd or Ga.

Compounds of another family have the following structures:

Embedded imageIn the formula, R1 to R9 each represent CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR10,
CONHR10, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH,
OR10 or a functional group having a molecular weight of 100,000 daltons or less), CH_TwoCO_TwoR10, CH_TwoC
ONHR10, CH = CHCH_TwoOH, CH = CHCH_TwoOR10, CH (OH) C
H_Three, CH (OR10) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons)
), Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted
Substituted alkynyl, amide, ester, NR10R10, CN, OH, OR10, C
HO, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR1
0, (CH_Two)_nOR10 (where n = 1, 2, 3, 4, and R10 is 100,000 daltons)
), (CH_Two)_nCO_TwoR10 (wherein R10 is H, physiologically
Acceptable salts, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl,
A substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3,
, 4), (CH_Two)_nCONHR10, (CH_Two)_nCON (R10)_Two, CO_TwoR10, C
ONHR10, CONR10R10, SR10 (R10 is less than 100000 Dalton
Functional group), SO_ThreeH, SO_ThreeR10, SO_TwoNHR10, SO_TwoN (R10)_Two,
SO_TwoN (R10)_Three ⁺X^-(Wherein, R10 is a functional group having a molecular weight of 100,000 daltons or less,
X is a charge-balancing ion), protein or biomolecule, or 100,000 daltons or less.
The lower functional group; M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵Is a mixture of
. M can also be Ga.

Yet another family of compounds has the structure:

Embedded image In the formula, R1 to R12 are each CH ₂ CH ₃ , CHＣＨCH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is a halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R13,
CONHR13, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR13 or 100,000 Daltons following functional _{groups), CH 2 CO 2 R13,} CH 2 C
_{ONHR13, CH = CHCH 2 OH,} CH = CHCH 2 OR13, CH (OH) C
_{H 3, CH (OR13) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR13R13, CN, OH, OR13, C
_{HO, (CH 2) n OH} , (CH 2) n SH, (CH 2) n O- alkoxy, (CH _{2) n} SR1
3, (CH ₂ ) _n OR 13 (where n = 1, 2, 3, 4, and R 13 is a functional group of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R 13 (where R 13 is H , Physiologically acceptable salts, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl,
A substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3,
_{, 4), (CH 2)} n CONHR13, (CH 2) n CON (R13) 2, CO 2 R13, C
ONHR13, CONR13R13, SR13 (R13 is a functional group of 100000 daltons or less), SO ₃ H, SO ₃ R13, SO ₂ NHR13, SO ₂ N (R13) ₂ ,
SO ₂ N (R13) ₃ ⁺ X ⁻ (where R13 is a functional group of up to 100,000 daltons and X is a charge balancing ion), a protein or biomolecule or a functional group of up to 100,000 daltons; Is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or up to 100,000 daltons Is a functional group. M can also be Pd or Ga.

Yet another family of compounds has the structure:

Embedded image In the formula, R1 to R15 are each CH ₂ CH ₃ , CHＣＨCH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is a halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R16,
CONHR16, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR16 or 100,000 Daltons following functional _{groups), CH 2 CO 2 R16,} CH 2 C
_{ONHR16, CH = CHCH 2 OH,} CH = CHCH 2 OR16, CH (OH) C
_{H 3, CH (OR16) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR16R16, CN, O, S, NHR16
, OH, OR16, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR16,} (CH 2) n OR16 ( wherein, n = 1 , 2, 3, 4, and R16 are functional groups of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R16 (where R
16 is H, a physiologically acceptable salt, alkyl (1 to 6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); (CH ₂ ) _n CONHR16, (CH ₂ ) _n CON (R16
) ₂ , CO ₂ R16, CONHR16, CONR16R16, SR16 (wherein R1
6 is a functional group of 100000 Dalton or less), SO ₃ H, SO ₃ R16, SO ₂ NHR
16, SO ₂ N (R16) ₂ , SO ₂ N (R16) ₃ ⁺ X ⁻ (wherein R16 is a functional group of 100,000 daltons or less and X is a charge balancing ion), protein or biomolecule or 100,000 daltons has the following functional group; M is a mixture of an in ^113, an in ¹¹⁵ or an in ^{11 3} and an in ^115; Z is a halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, Substituted alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr or Rh, preferably Pd, Pt,
It may be Ga, Al, Ru, Sn or Zn.

Yet another family of compounds has the structure:

Embedded image In the formula, R1 to R14 are each CH ₂ CH ₃ , CH 2CH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is a halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R15,
CONHR15, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR15 or 100,000 Daltons following functional _{groups), CH 2 CO 2 R15,} CH 2 C
_{ONHR15, CH = CHCH 2 OH,} CH = CHCH 2 OR15, CH (OH) C
_{H 3, CH (OR15) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR15R15, CN, O, S, NHR15
, OH, OR15, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR15,} (CH 2) n OR15 ( wherein, n = 1 , 2, 3, 4, and R15 are functional groups of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R15 (wherein R
15 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); (CH ₂ ) _n CONHR15, (CH ₂ ) _n CON (R15
) ₂ , CO ₂ R15, CONHR15, CONR15R15, SR15 (wherein R1
5 is a functional group of 100000 Dalton or less), SO ₃ H, SO ₃ R15, SO ₂ NHR
15, SO ₂ N (R15) ₂ , SO ₂ N (R15) ₃ ⁺ X ⁻ (wherein R15 is a functional group of 100,000 daltons or less and X is a charge balancing ion), protein or biomolecule or 100,000 daltons has the following functional group; M is a mixture of an in ^113, an in ¹¹⁵ or an in ^{11 3} and an in ^115; Z is a halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, Substituted alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr or Rh, preferably Pd, Pt,
It may be Ga, Al, Ru, Sn or Zn.

Yet another family of compounds has the structure:

Embedded image In the formula, R1 to R15 are each CH ₂ CH ₃ , CHＣＨCH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is a halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R16,
CONHR16, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR16 or 100,000 Daltons following functional _{groups), CH 2 CO 2 R16,} CH 2 C
_{ONHR16, CH = CHCH 2 OH,} CH = CHCH 2 OR16, CH (OH) C
_{H 3, CH (OR16) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR16R16, CN, O, S, NHR16
, OH, OR16, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR16,} (CH 2) n OR16 ( wherein, n = 1 , 2, 3, 4, and R16 are functional groups of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R16 (where R
16 is H, a physiologically acceptable salt, alkyl (1 to 6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); (CH ₂ ) _n CONHR16, (CH ₂ ) _n CON (R16
) ₂ , CO ₂ R16, CONHR16, CONR16R16, SR16 (R16 is 10
0000 Dalton or less), SO ₃ H, SO ₃ R16, SO ₂ NHR16,
SO ₂ N (R16) ₂ , SO ₂ N (R16) ₃ ⁺ X ⁻ (where R16 is a functional group of 100,000 daltons or less and X is a charge balance ion), protein or biomolecule, or 100,000 daltons M is In ¹¹³ , In ¹¹⁵ or In ¹¹³ or I
a mixture of n ¹¹⁵ ; Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
It is a protein or biomolecule or a functional group of 100000 dalton or less. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr or Rh, preferably Pd, Pt,
It may be Ga, Al, Ru, Sn or Zn.

Yet another family of compounds has the structure:

Embedded image In the formula, R1 to R12 are each CH ₂ CH ₃ , CHＣＨCH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is a halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R13,
CONHR13, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR13 or 100,000 Daltons following functional _{groups), CH 2 CO 2 R13,} CH 2 C
_{ONHR13, CH = CHCH 2 OH,} CH = CHCH 2 OR13, CH (OH) C
_{H 3, CH (OR13) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR13R13, CN, O, S, NHR13
, OH, OR13, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR13,} (CH 2) n OR13 ( wherein, n = 1 , 2, 3, 4, and R13 are functional groups of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R13 (wherein R
13 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); (CH ₂ ) _n CONHR13, (CH ₂ ) _n CON (R13
) ₂ , CO ₂ R13, CONHR13, CONR13R13, SR13 (R13 is 10
0000 Dalton or less), SO ₃ H, SO ₃ R13, SO ₂ NHR13,
SO ₂ N (R13) ₂ , SO ₂ N (R13) ₃ ⁺ X ⁻ (where R13 is a functional group of 100,000 daltons or less and X is a charge-balanced ion), protein or biomolecule, or 100,000 daltons M is In ¹¹³ , In ¹¹⁵ or In ¹¹³ and I
a mixture of n ¹¹⁵ ; Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
It is a protein or biomolecule or a functional group of 100000 dalton or less. M can also be Pd, Pt, Ga or Al.

Yet another family of compounds has the structure:

Embedded image In the formula, R1 to R14 are each CH ₂ CH ₃ , CH 2CH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is a halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R15,
CONHR15, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR15 or 100,000 Daltons following functional _{groups), CH 2 CO 2 R15,} CH 2 C
_{ONHR15, CH = CHCH 2 OH,} CH = CHCH 2 OR15, CH (OH) C
_{H 3, CH (OR15) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR15R15, CN, O, S, NHR15
, OH, OR15, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR15,} (CH 2) n OR15 ( wherein, n = 1 , 2, 3, 4, and R15 are functional groups of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R15 (wherein R
15 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); (CH ₂ ) _n CONHR15, (CH ₂ ) _n CON (R15
) ₂ , CO ₂ R15, CONHR15, CONR15R15, SR15 (wherein R1
5 is a functional group of 100000 Dalton or less), SO ₃ H, SO ₃ R15, SO ₂ NHR
15, SO ₂ N (R15) ₂ , SO ₂ N (R15) ₃ ⁺ X ⁻ (wherein R15 is a functional group of 100,000 daltons or less and X is a charge balancing ion), protein or biomolecule or A, B, C, D are: C, N, O ⁺
, O, S, Te, P, N ⁺ (R15) X ⁻ , wherein R15 is a functional group of up to 100,000 daltons and X is a charge balancing ion, or a combination thereof;
Is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or up to 100,000 daltons Is a functional group. M can also be Pd, Pt, Ga or Al.

Yet another family of compounds has the structure:

Embedded image In the formula, R1 to R18 are each CH ₂ CH ₃ , CH 2CH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R19,
CONHR19, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR 19 or a functional group having a molecular weight of 100,000 daltons or less), CH ₂ CO ₂ R 19, CH ₂ C
_{ONHR19, CH = CHCH 2 OH,} CH = CHCH 2 OR19, CH (OH) C
_{H 3, CH (OR19) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR19R19, CN, O, S, NHR19
, OH, OR19, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR19,} (CH 2) n OR19 ( wherein, n = 1 , 2,3,4, and R19 are the following functional groups 100,000 _{daltons), (CH 2) n CO} 2 R19 ( wherein, R
19 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); _{(CH 2) n CONHR19, (} CH 2) n CON (R19
) ₂ , CO ₂ R19, CONHR19, CONR19R19, SR19 (R19 is 10
0000 Dalton or less), SO ₃ H, SO ₃ R19, SO ₂ NHR19,
SO ₂ N (R19) ₂ , SO ₂ N (R19) ₃ ⁺ X ⁻ (where R19 is a functional group of 100,000 daltons or less and X is a charge-balancing ion), protein or biomolecule, or 100,000 daltons A, B, C, D, E, F, G, H are: C
, N, O ⁺ , O, S, Te, P, N ⁺ (R19) X ⁻ , wherein R19 is a functional group of up to 100,000 daltons and X is a charge-balancing ion, or a combination thereof. Yes; M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or 100000
It is a functional group of Dalton or less. M can also be Pd, Pt, Ga or Al.

Yet another family of compounds has the structure:

Embedded image In the formula, R1 to R12 are each CH ₂ CH ₃ , CHＣＨCH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2 X, CH} = CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (
X) ₂ C (X) ₃ (where X is a halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R13
, CONHR13, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH
Are the following functional group OR13 or 100,000 _{Daltons), CH 2 CO 2 R13,} CH 2 CONHR13, CH = CHCH 2 OH, CH = CHCH 2 OR13, CH (OH)
CH ₃ , CH (OR 13) CH ₃ , H, halide, alkyl, cyclic alkyl (3 to 6
Carbon), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl,
Substituted alkynyl, amide, ester, NR13R13, CN, O, S, NHR1
3, OH, OR13, CHO, (CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR13,} (CH 2) n OR13 ( wherein, n = 1, 2, 3, 4, and R13 is a functional group having a molecular weight of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R 13 (wherein,
R13 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); (CH ₂ ) _n CONHR13, (CH ₂ ) _n CON (R1
3) ₂ , CO ₂ R13, CONHR13, CONR13R13, SR13 (in the formula, R
13 is a functional group of 100,000 daltons or less), SO ₃ H, SO ₃ R13, SO ₂ NH
R13, SO ₂ N (R13) ₂ , SO ₂ N (R13) ₃ ⁺ X ⁻ (where R13 is a functional group of 100,000 daltons or less and X is a charge balancing ion), protein or biomolecule or A functional group of up to 100,000 daltons; Z is halide, acetate, O
H, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons.

Another family of compounds has the following structures:

Embedded image In the formula, R1 to R15 are each CH ₂ CH ₃ , CHＣＨCH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is a halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R16,
CONHR16, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR16 or 100,000 Daltons following functional _{groups), CH 2 CO 2 R16,} CH 2 C
_{ONHR16, CH = CHCH 2 OH,} CH = CHCH 2 OR16, CH (OH) C
_{H 3, CH (OR16) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR16R16, CN, O, S, NHR16
, OH, OR16, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR16,} (CH 2) n OR16 ( wherein, n = 1 , 2, 3, 4, and R16 are functional groups of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R16 (where R
16 is H, a physiologically acceptable salt, alkyl (1 to 6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); (CH ₂ ) _n CONHR16, (CH ₂ ) _n CON (R16
) ₂ , CO ₂ R16, CONHR16, CONR16R16, SR16 (wherein R1
6 is a functional group of 100000 Dalton or less), SO ₃ H, SO ₃ R16, SO ₂ NHR
16, SO ₂ N (R16) ₂ , SO ₂ N (R16) ₃ ⁺ X ⁻ (wherein R16 is a functional group of 100,000 daltons or less and X is a charge balancing ion), protein or biomolecule or Z is a functional group of 100000 daltons or less; Z is halide, acetate, OH
, Alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule, or a functional group of up to 100,000 daltons.

Yet another family of compounds has the structure:

Embedded image In the formula, R1 to R14 are each CH ₂ CH ₃ , CH 2CH ₂ , CH ＝ CHCH ₂ N
_{(CH 3) 2, CH =} CHCH 2 N + (CH 3) 3 X - ( wherein, X is a charge balancing ion), C (X
) ₂ C (X) ₃ (where X is a halogen), CHO, COCH ₃ , CO ₂ H, CO ₂ R15,
CONHR15, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH,
OR15 or 100,000 Daltons following functional _{groups), CH 2 CO 2 R15,} CH 2 C
_{ONHR15, CH = CHCH 2 OH,} CH = CHCH 2 OR15, CH (OH) C
_{H 3, CH (OR15) CH} 3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR15R15, CN, O, S, NHR15
, OH, OR15, CHO, ( CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR15,} (CH 2) n OR15 ( wherein, n = 1 , 2, 3, 4, and R15 are functional groups of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R15 (wherein R
15 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4); (CH ₂ ) _n CONHR15, (CH ₂ ) _n CON (R15
) ₂ , CO ₂ R15, CONHR15, CONR15R15, SR15 (wherein R1
5 is a functional group of 100000 Dalton or less), SO ₃ H, SO ₃ R15, SO ₂ NHR
15, SO ₂ N (R15) ₂ , SO ₂ N (R15) ₃ ⁺ X ⁻ (wherein R15 is a functional group of 100,000 daltons or less and X is a charge balancing ion), protein or biomolecule or 100,000 daltons has the following functional group; M is a mixture of an in ^113, an in ¹¹⁵ or an in ^{11 3} and an in ^115; Z is a halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, Substituted alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons. M is Ag, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Hf, Ho,
La, Lu, Mo, Mg, Nd, Pb, Pr, Rh, Sb, Sc, Sm, Sn,
Tb, Th, Ti, Tl, Tm, U, V, Y, Yb or Zr, preferably Pd;
It may be Pt, Ga, Al, Ru, Sn or Zn.

Yet another family of compounds has the structure:

Embedded image Wherein In is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ;
12 are CH ₂ CH ₃ , CH = CH ₂ , CH = CHCH ₂ N (CH ₃ ) ₂ , CH
_{^{= CHCH 2 N + (CH 3}} ) 3 X - ( wherein, X is a charge balancing _{ion), C (X) 2 C} (X) 3 ( wherein, X is a _{halogen), CHO, COCH 3, CO} 2 H , CO ₂ R13, CONHR13
, CH = CHCHO, CH ₂ Y (where Y = H, halogen, OH, OR13 or 10
0000 Dalton or less of a functional _{group), CH 2 CO 2 R13,} CH 2 CONHR13,
CH = CHCH ₂ OH, CH = CHCH ₂ OR13, CH (OH) CH ₃ , CH (OR
13) CH _3, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR13R13, CN, O, S, NHR13, OH, OR13
_{, CHO, (CH 2) n} OH, (CH 2) n SH, (CH 2) n O- alkoxy, (CH _{2) n} S
_{R13, (CH 2) n OR13} ( wherein, n = 1, 2, 3, 4, and R13 are the following functional groups 100,000 _{daltons), (CH 2) n CO} 2 R13 ( wherein, R13 is H A physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1,2
(3, 4), (CH ₂ ) _n CONHR13, (CH ₂ ) _n CON (R13) ₂ , CO ₂ R13
, CONHR13, CONR13R13, SR13 (wherein, R13 is the following functional groups 100,000 _{daltons), SO 3 H, SO 3} R13, SO 2 NHR13, SO 2 N (
R13) ₂ , SO ₂ N (R13) ₃ ⁺ X ⁻ (where R13 is a functional group of 100,000 daltons or less and X is a charge balance ion), protein or biomolecule or 100,000
Z is a halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or a functional group of 100,000 daltons or less.

Two other families of compounds have the structures of compounds I and II below:

Embedded image Wherein M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; R 1, R 2 and R 3 can be the same or different and are CO ₂ H, C
_{O 2 R4, CONR4, CH 3} Y ', CONR4R4, NH 2, N (R4) 2, or N (
R4) ₃ ⁺ Z ^- in a, in the formula, Y 'is halogen, OH, OR @ 4, or molecular weight 100,0
R4 is a functional group having a molecular weight of 100,000 daltons or less, and Z is a physiologically acceptable charge balance ion, provided that R4 is a mono- or di-carboxy group of an amino acid. Not an acid, R5 is a methylene or ethylene group, X is H, vinyl, ethyl, acetyl, or formyl, and Y is methyl or formyl. M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu, Fe, Ga,
Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd, Pb, Pd, Pr,
Pt, Rh, Sb, Sc, Sm, Tb, Th, Ti, Tl, Tm, U, V, Y,
It can also be Yb or Zr, preferably In, Pd or Pt.

In yet another aspect, the present invention is directed to a free base or metal complex having one structure of the following compounds III and IV:

Embedded image Wherein M is 2H or a metal cation, R1, R2 and R3 can be the same or different and are CO ₂ H, C
_{O 2 R4, CONR4, CH 3} Y ', CONR4R4, NH 2, N (R4) 2, N (R4
) ₃ ⁺ Z ⁻ , or CONHR6OR7, wherein R6 is a divalent moiety composed of n alkylene groups and (n−1) oxygen, and each oxygen is formed by two ether bonds. Linked to an alkylene group, R7 is alkyl, and Z is a physiologically acceptable charge-balancing ion, provided that at least one R6 group is present in the structure; X is H, vinyl , Ethyl, acetyl or formyl, and Y is methyl or formyl. The aforementioned definition, and in any of the herein, the term "alkylene" refers to a divalent radical derived from an alkane having a free valence on different carbon carbon atoms, i.e. -C _n H _2n - in the meaning of is there. Preferably, M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu
, Fe, Ga, Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd, Pb
, Pd, Pr, Pt, Rh, Sb, Sc, Sm, Sn, Tb, Th, Ti, Tl
, Tm, U, V, Y , Yb, Zn or Zr, most preferably Zn, Sn, In ^{11 3,} a mixture of an In ¹¹⁵ an In ¹¹³ and an In ^115, a Pd, or Pt.

In yet another aspect, the invention relates to a metal complex having one structure of the following compounds V and VI:

Embedded image Wherein M is 2H, In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; R 1, R 2 and R 3 can be the same or different and each X is H, vinyl, ethyl, acetyl, or Formyl, and Y is methyl or formyl. M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Fe, Ga, Gd,
Hf, Ho, In, La, Lu, Mn, Mo, Nd, Pb, Pd, Pr, Pt,
Rh, Sb, Sc, Sm, Tb, Th, Ti, Tl, Tm, U, V, Y, may even Yb or Zr, most preferably Pd, Pt, In ^113, a mixture of an In ¹¹⁵ or an In ¹¹³ and an In ¹¹⁵ It is.

In the above discussion of the invention and in the claims, the term "functional group having a molecular weight of 100,000 daltons or less" is used. The term refers to groups such as monoclonal antibodies, proteins, saccharides, oligomeric nucleosides, peptides and the like.
The terms alkyl, alkenyl, alkynyl, substituted alkenyl, substituted alkynyl and aryl, as used herein and in the claims, refer to substituents, preferably 1 to 10, 2 to 10, 2 to 2, respectively. A group having 10, 2 to 10, 2 to 10 and 6 to 10 carbon atoms is meant.

──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor Padeque Avinas S., USA 93117 Santa Barbara Encina Road 5673 Apartment 204 F-term (reference) 4C050 PA02 4C084 AA11 NA14 NA20 ZA812 ZA892 ZB262 ZC352 4C086 AA01 AA03 CB14 MA01 MA04 NA14 NA20 ZA36 ZA81 ZA89 ZB26 ZC35

Claims (30)

[Claims] 1. An element comprising at least two pyrroles, wherein the atom to which the pyrrole is bonded comprises In ¹¹³ or In ¹¹⁵ atoms complexed with nitrogen inside the pyrrole nucleus which is carbon or nitrogen or a combination thereof. A phototherapeutic compound, having the structure: Wherein R1, R2, R4 and R6 are methyl and R8, R10, R11 and R
12 is hydrogen and R7 and R8 are CH ₂ CH ₂ COR13 (wherein,
R13 is the moiety resulting from the removal of H from an amino acid), and Where R1 is CH (OR) Me, R is alkyl, R2 is a residue derived by removing H from an amino acid, and M is 2H, Ga, Z
other than n, Pd, In or Sn. A compound for phototherapy, which is a completely unsaturated porphyrin. 2. The phototherapy compound according to claim 1, wherein the nucleus is a tetrapyrrole nucleus. 3. The phototherapy compound according to claim 2, wherein the nucleus is a dihydro or tetrahydrotetrapyrrole nucleus. 4. The compound for phototherapy according to claim 3, wherein the compound has a tetrapyrrole nucleus whose bonding atom is carbon. 5. The phototherapeutic compound according to claim 4, which has one of the following compounds I and II. Embedded image Wherein M is In ¹¹³ Z, In ¹¹⁵ Z, or a mixture of In ¹¹³ Z and In ¹¹⁵ Z, wherein R 1, R 2 and R 3 may be the same or different and are each CO ₂ H,
CO ₂ R 4, CONR 4, CH ₃ Y ′, CONR 4 R 4, NH ₂ , N (R 4) ₂ , or N (R 4) ₃ ⁺ Z ⁻ , wherein Y ′ is halogen, OH, OR 4, or Ten
R4 is a functional group having a molecular weight of 100,000 daltons or less, R5 is a methylene group or an ethylene group, X is H, vinyl, ethyl, acetyl or formyl; Is methyl or formyl, and Z is a physiologically acceptable charge balance ion. 6. A free base or metal complex having one of the following compounds III and IV: Embedded image Wherein M is 2H or a metal cation and a physiologically tolerable charge-balanced ion bound to the metal cation, R1, R2 and R3 can be the same or different and each is CO ₂ H, CO ₂ R4, CONR4, CH ₃ Y ′, CONR
_{4R4, NH 2, N (R4} ) 2, N (R4) 3 + Z -, or a CONHR6OR7, wherein, R4 is an alkyl group, R6 includes n alkylene group (n minus 1) Is a divalent moiety consisting of two oxygens, each oxygen
R is alkyl, X is H, vinyl, ethyl, acetyl, or formyl; and Y is methyl or formyl; and the molecule comprises at least one It is characterized by having an R6 group. 7. M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er,
Eu, Fe, Ga, Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd,
Pb, Pd, Pr, Pt, Rh, Sb, Sc, Sm, Sn, Tb, Th, Ti,
The metal complex according to claim 6, which is Tl, Tm, U, V, Y, Yb, Zn or Zr. 8. M is Zn, Sn, Pd, Pt, In.¹¹³, In¹¹⁵Or In ¹¹³ And In¹¹⁵The metal complex according to claim 7, which is a mixture of the following. 9. The compound for phototherapy according to claim 4, which has one structure of the following compounds V and VI. Embedded image In the formula, M is 2H, In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ and I
n ¹¹³ , In ¹¹⁵ or a physiologically acceptable charge-balanced ion bound to a mixture of In ¹¹³ and In ¹¹⁵ , wherein R 1 and R 3 may be the same or different and are CO ₂ CH ₃ , CO ₂ , respectively.
H, CO ₂ R 4 or an amide, wherein R 4 is an alkyl or phenyl group, and R 2 is CO ₂ CH ₃ , CO ₂ H, CO ₂ R 4, amide, CH ₂ CO ₂ CH ₃ , CH ₂ C
O ₂ H, or CH ₂ CO ₂ R 4, wherein R 4 is an alkyl or phenyl group, R 5 is methylene or ethylene, X is H, vinyl, ethyl, acetyl or formyl; And Y is methyl or formyl. 10. The phototherapy compound according to claim 4, which has the following structure. Embedded image In the formula, R1 to R5 may be the same or different and are each CH ₂ CH ₃ , C
_{H = CH 2, CH = CHCH} 2 N (CH 3) 2, CH = CHCH 2 N + (CH 3) 3 X -, C (
Y1) ₂ C (Y1) ₃ , CHO, COCH ₃ , CO ₂ H, CO ₂ R6, CONHR6, C
_{H = CHCHO, CH 2 Y,} CH = CHCH 2 OH, CH = CHCH 2 OR6, C
H (OH) CH ₃ , CH (OR 6) CH ₃ , H, halide, alkyl, cyclic alkyl (
3-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, NR6R6, CN, OH, OR6,
_{(CH 2) n OH, (} CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR6,} (C
_{H 2) n OR6, (CH} 2) n CO 2 R6, (CH 2) n CONHR6, (CH 2) n CON (R
6) ₂ , CO ₂ R6, CONHR6, CONR6R6, SR6, SO ₃ H, SO ₃ R
_{6, SO 2 NHR6, SO 2} N (R6) 2, SO 2 N (R6) 3 + X - a is; M is a mixture of an In ^113, an In ¹¹⁵ or an In ¹¹³ and an In ^115; Z is halide , Acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons; Y1 is halogen; Y is H, halogen, OH R6 is a functional group of up to 100,000 daltons; R7 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, X1 is a charge-balancing ion; and X is O, 2H, (H, OH), S, (H, OR6), or alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl. It is a ketone protecting group. 11. The phototherapeutic compound according to claim 10, wherein: R1 is CH ＝ CH ₂ , CHO, Et, COCH ₃ and R2 is CO ₂ CH ₃ , CO ₂ H or amide. , R3 and R4 is H, R5 is a CH _3, X is a O, M is a mixture of an in ^113, an in ¹¹⁵ or an in ¹¹³ and an in ^115, Z is a halide, acetate Or OH; a compound for phototherapy. 12. The compound for phototherapy according to claim 4, which has the following structure. Embedded image In the formula, R1 to R17 are each H, halide, alkyl, cyclic alkyl (3
6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, _{ester, C (X) 2 C (} X) 3 ( wherein, X is a halogen)
, NR18R18, CN, OH, OR18 , CHO, COCH 3, (CH 2) n OH
_{, (CH 2) n SH,} CH (OR18) CH 3, (CH 2) n O- alkoxy, (CH _{2) n} S
_{R18, (CH 2) n OR18} ( wherein, n = 1, 2, 3, 4, and R5 are the following functional groups 100,000 _{daltons), (CH 2) n CO} 2 R18 ( wherein, R18 is H Physiologically acceptable salts, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl or substituted alkynyl, and n = 1, 2, 3, 4)
, (CH ₂ ) _n CONHR18, (CH ₂ ) _n CON (R18) ₂ , CO ₂ R18, CONH
R18, CONR18R18, SR18 (wherein, R18 is the following functional groups 100,000 _{daltons), SO 3 X, SO 3} R18, SO 2 NHR18, SO 2 N (R18) 2,
SO ₂ N (R18) ₃ ⁺ X ⁻ (where R18 is a functional group of up to 100,000 daltons and X is a charge balancing ion); A, B, C and D are: C, N, O ⁺ , O,
^{S, Te, P, N +} (R19) X - ( wherein, R19 is the following functional groups 100,000 daltons and X is a charge balancing ion), or a combination thereof; M is an In ^{1 13} , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; Z is a halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons It is. 13. The compound for phototherapy according to claim 4, which has the following structure. Embedded image In the formula, R1 to R24 are each H, halide, alkyl, cyclic alkyl (3
6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, _{ester, C (X) 2 C (} X) 3 ( wherein, X is a halogen)
, NR25R25, CN, OH, OR25 , CHO, COCH 3, (CH 2) n OH
_{, (CH 2) n SH,} CH (OR25) CH 3, (CH 2) n O- alkoxy, (CH _{2) n} S
R25, (CH ₂ ) _n OR 25 (where n = 1, 2, 3, 4, and R 25 is a functional group of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R 25 (where R 25 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl or substituted alkynyl, and n = 1,2
(3, 4), (CH ₂ ) _n CONHR25, (CH ₂ ) _n CON (R25) ₂ , CO ₂ R25
, CONHR25, CONR25R25, SR25 (wherein, R25 is the following functional groups 100,000 _{daltons), SO 3 H, SO 3} R25, SO 2 NHR25, SO 2 N (
_{R25) 2, SO 2 N (} R25) 3 + X - a is (wherein, R25 is the following functional groups 100,000 daltons and X is a charge balancing ion); M is an In ^113, an In ¹¹⁵ or I
a mixture of n ¹¹³ and In ¹¹⁵ ; A, B, C, D, E, F are: C, N, O ⁺ , O
, S, Te, P, N ⁺ (R25) X ⁻ , wherein R25 is a functional group of up to 100,000 daltons and X is a charge-balancing ion, or a combination thereof; Z is a halide, Acetate, OH, alkyl, aryl, substituted aryl, alkenyl,
A substituted alkenyl, alkynyl, substituted alkynyl, or protein or biomolecule or functional group of up to 100,000 daltons. 14. The compound for phototherapy according to claim 4, which has the following structure. Embedded image In the formula, R1 to R13 are each H, halide, alkyl, vinyl, cyclic alkyl (3 to 6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, CH ＝ CHCH ₂ N (CH ₃ ) ₂ , C
^{_{H = CHCH 2 N + (CH}} 3) 3 X - ( wherein, X is a charge balancing _{ion), C (X) 2 C} (X) 3 ( wherein, X is a halogen), NR14R14, CN, OH, OR14 , COCH ₃ , (C
_{H 2) n OH, (CH} 2) n SH, (CH 2) n O- _{alkoxy, CH (OH) CH 3,} CH (
_{OR14) CH 3, (CH 2} ) n SR14, (CH 2) n OR14 ( wherein, n = 1, 2, 3
, 4 and R14 are functional groups of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R14
Wherein R14 is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH ₂ ) _n CONHR14, (CH ₂ ) _n C
ON (R14) ₂ , CO ₂ R14, CONHR14, CONR14R14, SR14
(Wherein R14 is a functional group of 100000 daltons or less), SO ₃ X, SO ₃ R14,
_{SO 2 NHR14, SO 2 N (} R14) 2, SO 2 N (R14) 3 + X - ( wherein, R14 is 10
0000 Daltons following functional groups, and X is a charge balancing ion); M is a mixture of In ^{1 13,} In ¹¹⁵ or an In ¹¹³ and an In ^115; Z is a halide, acetate, OH, alkyl, aryl, A substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or a functional group of up to 100,000 daltons. 15. The phototherapy compound according to claim 4, which has the following structure. Embedded imageIn the formula, R1 to R13 are each H, halide, alkyl, cyclic alkyl (3 to
6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl
, Substituted alkynyl, amide, ester, CH = CHCH_TwoN (CH_Three)_Two, CH = C
HCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X)_TwoC (X)_Three(Where X
Is halogen), NR14R14, CN, OH, OR14, CHO, (CH_Two)_nOH
, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, CH (OH) CH_Three, CH (OR14)
CH_Three, (CH_Two)_nSR14, (CH_Two)_nOR14 (where n = 1, 2, 3, 4, and
R14 is a functional group having a molecular weight of 100,000 daltons or less), (CH_Two)_nCO_TwoR14 (wherein, R
14 is H, a physiologically acceptable salt, alkyl (1 to 6 carbons), aryl, substituted
Reel, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl
, And n = 1, 2, 3, 4), (CH_Two)_nCONHR14, (CH_Two)_nCONH (R1
4)_Two, CO_TwoR14, CONHR14, CONR14R14, SR14 (wherein, R
14 is a functional group having a molecular weight of 100,000 daltons or less), SO_ThreeH, SO_ThreeR14, SO_TwoNH
R14, SO_TwoN (R14)_Two, SO_TwoN (R14)_Three ⁺X^-(Where R14 is 100,000 dal
And X is a charge balance ion); M is In¹¹³, In ¹¹⁵ Or In¹¹³And In¹¹⁵Z is halide, acetate, OH,
Alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl
, Or substituted alkynyl, protein or biomolecule or functionality below 100,000 daltons
Group. 16. The phototherapy compound according to claim 4, which has the following structure. Embedded image Wherein R1 and R2 are CO ₂ R14 (where R14 is alkyl or aryl);
R 3, R 6, R 8, R 12 are each Me 4 R 5 CH = CH ₂ , or CH (OR 14) CH ₃ (wherein CO ₂ H (or a salt thereof), SO ₂ Ph, CN or a combination thereof) , R14 is alkyl or aryl) R4, R7, R13, R10 is H R9 and R11 are each, in CH ₂ CH ₂ CO ₂ R15 (wherein, R15 is alkyl or H or a salt of a carboxylic acid) M, an in ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ Z is halide, acetate, or OH. 17. The phototherapy compound according to claim 4, which has the following structure. Embedded image Wherein A, B, C, D and E are C, N, N ⁺ R (where R is a charged or uncharged alkyl) or a combination thereof; M is In ¹¹³ , In ¹¹⁵ or A mixture of In ¹¹³ and In ¹¹⁵ ; and Z is halide, acetate, or OH. 18. The compound for phototherapy according to claim 4, which has the following structure. Embedded image In the formula, R 1 to R 4 are SO ₃ H (or a salt thereof), SO ₂ NHR 5, CO ₂ H (or a salt thereof), CONHR 5, OH, OR 5 (where R 5 is an alcohol or ether-containing group)
), Amide, N (CH ₃ ) ₂ , N (Et) ₂ , M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ , and Z is halide, acetate, OH. 19. The compound for phototherapy according to claim 4, which has the following structure. Embedded image In the formula, R1 to R14 each represent H, halide, methyl, ethyl, alkyl, cyclic alkyl (3 to 6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, C (X ) ₂ C (X) ₃ (where
X is a halogen), NR15R15, CN, OH, OR15, CHO, COCH 3,
_{CH (OR15) CH 3, (} CH 2) n OH, (CH 2) n SH, (CH 2) n O- _{alkoxy, (CH 2) n SR15,} (CH 2) n OR15 ( wherein, n = 1 , 2, 3, 4, and R1
5 is a functional group having a molecular weight of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R 15 (wherein R 15
Is H, a physiologically acceptable salt, alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkyne, and n = 1, 2, 3, 4)
, (CH ₂ ) _n CONHR15, (CH ₂ ) _n CON (R15) ₂ , CO ₂ R15, CONH
R15, CONR15R15, SR15 (wherein, R15 is a functional group of 100,000 daltons or less and n = 1, 2, ₃ , 4), SO ₃ H, SO ₃ R15, SO ₂ NHR
15, SO ₂ N (R15) ₂ , SO ₃ N (R15) ₃ ⁺ X ⁻ (where R15 is a functional group of 100,000 daltons or less and X is a charge balance ion); M is In ¹¹³ , a mixture of an in ^{11 5} or an in ¹¹³ and an in ^115; Z is a halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl,
Substituted alkynyl, or a functional group of up to 100,000 daltons, protein or biomolecule. 20. The compound for phototherapy according to claim 4, which has the following structure. Embedded imageWherein R1 to R8 are each ethyl or methyl; R9 is CH_Three, SO_TwoNH (CH_TwoCH_TwoO)_nCH_Three(n = 1 to 1000), SO_TwoN ((C
H_TwoCH_TwoO)_nCH_Three)_Two(n = 1 to 1000), SO_TwoNH (CH_Two)_nOH (n = 1 to 1000),
CH_Three, SO_TwoN ((CH_TwoCH_Two)_nOH)_Two(n = 1 to 1000); SO_TwoNC ((N (CH_Three)_Two) _Two ; SO_TwoNH (CH_Two)_nN (CH_Three)_Two(n = 1 to 1000); SO_TwoNH (CH_Two)_nSH (n =
1 to 1000); SO_TwoNHC (CH_TwoCH_TwoOH)_Three; SO_TwoNHCH_TwoCO_TwoH (or its
Salt); SO_TwoNH (CH_Two)_nCH (NH_Two) CO_TwoH (or a salt thereof) (n = 1 to 5); SO_Two NHCH_TwoCO_TwoR10 (R10 is alkyl or aryl); SO_TwoNH (CH_Two)_nC
H (NH_Two) CO_TwoR10 (R10 is alkyl, aryl) (n = 1 to 5);
M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵And Z is a mixture of
De, acetate, and OH. 21. The compound for phototherapy according to claim 4, which has the following structure. Embedded image Wherein, R1 to R8 are each ethyl or methyl, R9 _{is, CH 2 CO 2 NH (CH} 2 CH 2 O) n CH 3 (n = 1~1000), CH 2 CO 2 N ((
CH ₂ CH ₂ O) _n CH ₃ ) ₂ (n = 1 to 1000); CH ₂ CO ₂ NH (CH ₂ ) _n OH (n = 1 to 1000)
1000), CH ₂ CO ₂ N ((CH ₂ CH ₂ ) _n OH) ₂ (n = 1 to 1000); CH ₂ CO ₂ NC ((
N (CH ₃ ) ₂ ) ₂ ; CH ₂ CO ₂ NH (CH ₂ ) _n N (CH ₃ ) ₂ (n = 1 to 1000); CH ₂ CO ₂ N (CH ₂ ) _n SH (n = 1 to 1000) ); CH ₂ CO ₂ NHC (CH ₂ CH ₂ OH) ₃ ; CH ₂ C
O ₂ NHCH ₂ CO ₂ H (or a salt thereof); CH ₂ CO ₂ NH (CH ₂ ) _n CH (NH ₂ ) CO ₂
H (or a salt thereof) (n = 1~5); CH 2 CO 2 NHCH 2 CO 2 R10 (R10 is alkyl, _{aryl); CH 2 CO 2 NH (} CH 2) n CH (NH 2) CO 2 R10 (R10 is alkyl, aryl) and (n = 1 to 5), M is a mixture of an in ^113, an in ¹¹⁵ or an in ¹¹³ and an in ^115, and Z is a halide, acetate, is OH. 22. The phototherapy compound according to claim 4, which has the following structure. Embedded image In the formula, R1 to R14 are each H, halide, alkyl, cyclic alkyl (3 to
6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, CH ＝ CHCH ₂ N (CH ₃ ) ₂ , CH ＝ C
_{^{HCH 2 N + (CH 3)}} 3 X - ( wherein, X is a charge balancing _{ion), C (X) 2 C} (X) 3 ( wherein, X
It is halogen), NR15R15, CN, OH, OR15, CHO, (CH 2) n OH
_{, (CH 2) n SH,} (CH 2) n O- _{alkoxy, CH (OH) CH 3,} CH (OR15)
CH ₃ , (CH ₂ ) _n SR 15, (CH ₂ ) _n OR 15 (where n = 1, 2, 3, 4, and R 15 is a functional group of 100,000 daltons or less), (CH ₂ ) _n CO ₂ R15 (wherein, R
15 is H, a physiologically acceptable salt, alkyl (1 to 6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkyne, and n = 1, 2, 3,
4), (CH ₂ ) _n CONHR15, (CH ₂ ) _n CON (R15) ₂ , CO ₂ R15, CO
NHR15, CONR15R15, SR15 (wherein, R15 is the following functional groups 100,000 _{daltons), SO 3 H, SO 3} R15, SO 2 NHR15, SO 2 N (R15
) ₂ , SO ₂ N (R15) ₃ ⁺ X ⁻ (wherein, R15 is a functional group of 100,000 daltons or less and X is a charge balancing ion); A, B, C, D are: C, N , O ⁺ , O, S,
Te, P, or a combination thereof; M is a mixture of an In ^113, an In ¹¹⁵ or an In ¹¹³ and In ^{1 15;} Z is a halide, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl , Substituted alkynyls, proteins or biomolecules or functional groups up to 100,000 daltons. 23. The compound for phototherapy according to claim 4, which has the following structure. Embedded image In the formula, R1 to R14 are each H, halide, alkyl, cyclic alkyl (3 to
6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, C (X) ₂ C (X) ₃ (where X is halogen),
NR15R15, CN, OH, OR15, CHO, COCH 3, (CH 2) n OH, (
_{CH 2) n SH, (CH} 2) n O- _{alkoxy, (CH 2) n SR15,} (CH 2) n OR15 (
Wherein n = 1, 2, 3, 4, and R15 is a functional group of 100,000 daltons or less.
, (CH ₂ ) _n CO ₂ R15 (where R15 is H, a physiologically acceptable salt, alkyl
(1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH ₂ ) _n CON
_{HR15, (CH 2) n CON} (R15) 2, CO 2 R15, CONHR15, CON (
R15) ₂ (wherein, R15 is a functional group of 100,000 daltons or less), SR15 (where, R15 is a functional group of 100,000 daltons or less), SO ₃ H, SO ₃ R15, SO ₂ NHR15, SO ₂ N (R15) ₂ , SO ₂ N (R15) ₃ ⁺ X ⁻ (where R15 is 100000
Is a sub-Dalton functional group and X is a charge balancing ion); M is In ¹¹³ ,
In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ ; Z is halide, acetate, O
H, alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl or substituted alkynyl, or a functional group, protein or biomolecule of up to 100,000 daltons. 24. The compound for phototherapy according to claim 4, which has the following structure. Embedded image Wherein R1 is CH ₂ ＣＨCH ₂ , Et, CHO, or COCH ₃ , R4 is Me, R3 is H, R2 is CO ₂ CH ₃ , CO ₂ H, CO ₂ R7 ( R7 is alkyl, phenyl),
A and B are each O or NR5 (R5 is alkyl); X is O or NR6 (R6 is alkyl, amino acid, alcohol-containing group, or ether-containing group); and M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ , and Z is halide, acetate, or OH. 25. The compound for phototherapy according to claim 4, which has the following structure. Embedded imageIn the formula, R1 to R6 each represent CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR7, C
ONHR7, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
7 or 100000 Dalton or less), CH_TwoCO_TwoR7, CH_TwoCONHR
7, CH = CHCH_TwoOH, CH = CHCH_TwoOR7, CH (OH) CH_Three, CH (O
R7) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR7R7, CN, O, S, NHR7, OH, OR7, CHO
, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR7, (
CH_Two)_nOR7 (where n = 1, 2, 3, 4, and R7 is a government of 100,000 daltons or less)
Active group), (CH_Two)_nCO_TwoR7 (wherein R7 is H, a physiologically acceptable salt,
Alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl
, Alkynyl or substituted alkynyl, and n = 1, 2, 3, 4), (CH_Two)_n
CONR7, CO_TwoR7, CONHR7, CONR10R7, SR7 (R7 is 1000
00 Dalton or less), SO_ThreeH, SO_ThreeR7, SO_TwoNHR7, SO_Two
N (R7)_Two, SO_TwoN (R7)_Three ⁺X^-(Wherein R7 is a functional group of 100,000 daltons or less.
And X is a charge balance ion), a protein or biomolecule or 100,000 dal
X is O, H_Two, (H, OH), (H, OR8) S, or
M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵Is a mixture of
Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alk;
Kenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or organism
Or a functional group of 100,000 daltons or less. 26. The phototherapy compound according to claim 4, which has the following structure. Embedded imageIn the formula, R1 to R8 are each CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR9, C
ONHR9, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
9 or 100000 Dalton or less), CH_TwoCO_TwoR9, CH_TwoCONHR
9, CH = CHCH_TwoOH, CH = CHCH_TwoOR9, CH (OH) CH_Three, CH (O
R9) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR9R9, CN, O, S, NHR9, OH, OR9, CHO
, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR9, (
CH_Two)_nOR9 (where n = 1, 2, 3, 4, and R9 is a government of 100,000 daltons or less)
Active group), (CH_Two)_nCO_TwoR9 (wherein R9 is H, a physiologically acceptable salt,
Alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl
, Alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH_Two) _n CONHR9, (CH_Two)_nCON (R9)_Two, CO_TwoR9, CONHR9, CONR
10R9, SR9 (R9 is a functional group of 100000 Dalton or less), SO_ThreeH, SO_Three R9, SO_TwoNHR9, SO_TwoN (R9)_Two, SO_TwoN (R9)_Three ⁺X^-(Where R9 is 1000
A functional group of less than or equal to 00 Dalton, and X is a charge-balancing ion), protein
Or a biomolecule or a functional group of 100,000 daltons or less;¹¹³, In¹¹⁵or
Is In¹¹³And In¹¹⁵Z is halide, acetate, OH, alkyl
, Aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted
Alkynyl, protein or biomolecule or a functional group of 100,000 daltons or less. 27. The compound for phototherapy according to claim 4, which has the following structure. Embedded image Wherein R1 is CH ＝ CH ₂ , Et, CHO, or COCH ₃ R5 is O or NR9 (R9 is alkyl) R7 is Me R3 is H R4 and R8 is H, CO ₂ CH ₃ , CH ₂ H (or the Salt), CO ₂ R10 (R10 is an alkyl or phenyl group), amide, CH ₂ CO ₂ CH ₃ , CH ₂ CO ₂ H (or a salt thereof), CO ₂ R10 (R10 is an alkyl or phenyl group) Or amide R2 is CO ₂ CH ₃ , CO ₂ H, CO ₂ R10 (R10 is an alkyl or phenyl group), or amide M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ Z is a halide, acetate Or OH. 28. The phototherapy compound according to claim 4, having the following structure. Embedded imageIn the formula, R1 to R5 are each CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR6, C
ONHR6, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
6 or 100000 Dalton or less), CH_TwoCO_TwoR6, CH_TwoCONHR
6, CH = CHCH_TwoOH, CH = CHCH_TwoOR8, CH (OH) CH_Three, CH (O
R6) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR6R6, CN, O, S, NHR6, OH, OR6, CHO
, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR6, (
CH_Two)_nOR6 (where n = 1, 2, 3, 4, and R6 is a government of 100,000 daltons or less)
Active group), (CH_Two)_nCO_TwoR6 wherein R6 is H, a physiologically acceptable salt,
Alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl
, Alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH_Two) _n CONR6, CO_TwoR6, CONHR6, CONR6R6, SR6 (wherein, R6
Is a functional group of 100000 Dalton or less), SO_ThreeH, SO_ThreeR6, SO_TwoNHR6,
SO_TwoN (R6)_Two, SO_TwoN (R6)_Three ⁺X^-(Wherein, R6 is a sensory of 100,000 daltons or less
And X is a charge balance ion), a protein or biomolecule or 10,000
X is O, NR6 (R6 is H, alkyl (1-10
Carbon), aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl,
Substituted alkynyl, amino acid, amino acid ester or functional group of 100000 dalton or less
A and B are O, NH, NR6 or a combination thereof; Z is Halai
De, acetate, OH, alkyl, aryl, substituted aryl, alkenyl, substituted
Alkenyl, alkynyl, substituted alkynyl, protein or biomolecule or 100,000
It is a functional group of Dalton or less. 29. The compound for phototherapy according to claim 4, which has the following structure. Embedded image In the formula: R1 is CH ＝ CH ₂ , Et, CHO, or COCH ₃ R4 is O or NR6 (R6 is alkyl) R5 is Me R3 is H R2 is CO ₂ CH ₃ , CH ₂ H, CO ₂ R7 (R7 Is an alkyl or phenyl group) or amide X is O, NR6 (R6 is an alkyl, amino acid, alcohol-containing group, or ether-containing group) M is In ¹¹³ , In ¹¹⁵ or a mixture of In ¹¹³ and In ¹¹⁵ Z is Halide and acetate, OH, and A and B are O or NR6, wherein R6 is alkyl. 30. The compound for phototherapy according to claim 4, which has the following structure. Embedded imageIn the formula, R1 to R6 each represent CH_TwoCH_Three, CH = CH_Two, CH = CHCH_TwoN (
CH_Three)_Two, CH = CHCH_TwoN⁺(CH_Three)_ThreeX^-(Where X is a charge balancing ion), C (X) _Two C (X)_Three(Where X is a halogen), CHO, COCH_Three, CO_TwoH, CO_TwoR7, C
ONHR7, CH = CHCHO, CH_TwoY (where Y = H, halogen, OH, OR
7 or 100000 Dalton or less), CH_TwoCO_TwoR7, CH_TwoCONHR
7, CH = CHCH_TwoOH, CH = CHCH_TwoOR7, CH (OH) CH_Three, CH (O
R7) CH_Three, H, halide, alkyl, cyclic alkyl (3-6 carbons), aryl,
Substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
Mid, ester, NR7R7, CN, O, S, NHR7, OH, OR7, CHO
, (CH_Two)_nOH, (CH_Two)_nSH, (CH_Two)_nO-alkoxy, (CH_Two)_nSR7, (
CH_Two)_nOR7 (where n = 1, 2, 3, 4, and R7 is a government of 100,000 daltons or less)
Active group), (CH_Two)_nCO_TwoR7 (wherein R7 is H, a physiologically acceptable salt,
Alkyl (1-6 carbons), aryl, substituted aryl, alkenyl, substituted alkenyl
, Alkynyl, or substituted alkynyl, and n = 1, 2, 3, 4), (CH_Two) _n CONR7, CO_TwoR7, CONHR7, CONR7R7, SR7 (R7 is 10,000
0 Dalton or less), SO_ThreeH, SO_ThreeR7, SO_TwoNHR7, SO_TwoN
(R7)_Two, SO_TwoN (R7)_Three ⁺X^-(Wherein R7 is a functional group of 100,000 daltons or less
, And X is a charge-balancing ion), protein or biomolecule or 100,000 daltons
X is O, H_Two, (H, OH), (H, OR7), S, or
M is In¹¹³, In¹¹⁵Or In¹¹³And In¹¹⁵Is a mixture of
Z is halide, acetate, OH, alkyl, aryl, substituted aryl, alk;
Kenyl, substituted alkenyl, alkynyl, substituted alkynyl, protein or organism
Or a functional group of 100,000 daltons or less.